Genomic Health (GHDX) 10-K 12 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Feb. 28, 2015	Jun. 30, 2014
Document and Entity Information
Entity Registrant Name	GENOMIC HEALTH INC
Entity Central Index Key	1131324
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$449.90
Entity Common Stock, Shares Outstanding		32,172,849
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$29,726	$33,279
Short-term marketable securities	73,934	72,071
Accounts receivable (net of allowance for doubtful accounts; 2014 - $3,628, 2013 - $1,907)	34,916	29,446
Prepaid expenses and other current assets	9,944	10,196
Total current assets	148,520	144,992
Property and equipment, net	21,860	18,290
Other assets	15,541	13,752
Total assets	185,921	177,034
Current liabilities:
Accounts payable	6,987	5,160
Accrued compensation and employee benefits	17,708	13,884
Accrued license fees	2,656	2,554
Accrued expenses and other current liabilities	10,444	7,356
Deferred revenues	335	586
Other current liabilities	208	292
Total current liabilities	38,338	29,832
Other liabilities	2,070	2,221
Commitments
Stockholders' equity:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.0001 par value; 100,000,000 shares authorized, 32,969,232 and 32,024,887 shares issued and 31,911,901 and 30,964,086 shares outstanding at December 31, 2014 and 2013, respectively	3	3
Additional paid-in capital	370,496	345,345
Accumulated other comprehensive (loss) income, net	-15	12
Accumulated deficit	-194,861	-170,269
Treasury stock, at cost, 1,061,331 shares at December 31, 2014 and 2013	30,110	30,110
Total stockholders' equity	145,513	144,981
Total liabilities and stockholders' equity	$185,921	$177,034

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Condensed Consolidated Balance Sheets
Accounts receivable, allowance for doubtful accounts	$3,628	$1,907
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,969,232	32,024,887
Common stock, shares outstanding	31,911,901	30,964,086
Treasury stock, at cost (in shares)	1,061,331	1,061,331

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Product revenues	$275,706	$259,192	$233,457
Contract revenues		2,403	1,716
Total revenues	275,706	261,595	235,173
Operating expenses:
Cost of product revenues	48,742	42,100	37,018
Research and development	56,064	66,333	49,104
Selling and marketing	134,858	110,602	93,553
General and administrative	59,669	54,392	47,064
Total operating expenses	299,333	273,427	226,739
Income (loss) from operations	-23,627	-11,832	8,434
Impairment of investments		-643
Interest income	192	222	295
Other income (expense), net	-764	-158	-58
Income (loss) before income taxes	-24,199	-12,411	8,671
Income tax expense	393	346	422
Net income (loss)	($24,592)	($12,757)	$8,249
Basic net income (loss) per share (in dollars per share)	($0.78)	($0.42)	$0.27
Diluted net income (loss) per share (in dollars per share)	($0.78)	($0.42)	$0.26
Shares used in computing basic net income (loss) per share	31,453	30,512	30,326
Shares used in computing diluted net income (loss) per share	31,453	30,512	32,152

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Condensed Consolidated Statements of Comprehensive Income (Loss)
Net income (loss)	($24,592)	($12,757)	$8,249
Other comprehensive income:
Unrealized gain (loss) on available-for-sale marketable securities, net of tax	-27	-3	45
Comprehensive income (loss)	($24,619)	($12,760)	$8,294

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Treasury Stock at Cost	Total
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2011	$3	$281,147	($30)	($165,761)		$115,359
Balance (in shares) at Dec. 31, 2011	29,761,000
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options for cash and vesting of restricted stock units		14,086				14,086
Issuance of common stock upon exercise of stock options for cash and vesting of restricted stock units (in shares)	1,025,000
Issuance of common stock upon settlement of employee stock purchase plan		3,406				3,406
Issuance of common stock upon settlement of employee stock purchase plan (in shares)	146,000
Issuance of restricted stock to directors in lieu of fees		172				172
Issuance of restricted stock to directors in lieu of fees (in shares)	6,000
Stock-based compensation expense related to employee stock options, restricted stock units and employee stock purchase plan		15,104				15,104
Repurchase of common stock					-30,095	-30,095
Repurchase of common stock (in shares)	-984,000
Net income (loss)				8,249		8,249
Unrealized gain (loss) on investments, net of tax			45			45
Balance at Dec. 31, 2012	3	313,915	15	-157,512	-30,095	126,326
Balance (in shares) at Dec. 31, 2012	29,954,000
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options for cash and vesting of restricted stock units		9,725				9,725
Issuance of common stock upon exercise of stock options for cash and vesting of restricted stock units (in shares)	926,000
Issuance of common stock upon settlement of employee stock purchase plan		4,018				4,018
Issuance of common stock upon settlement of employee stock purchase plan (in shares)	153,000
Issuance of restricted stock to directors in lieu of fees		230				230
Issuance of restricted stock to directors in lieu of fees (in shares)	8,000
Stock-based compensation expense related to employee stock options, restricted stock units and employee stock purchase plan		17,457				17,457
Repurchase of common stock					-15	-15
Repurchase of common stock (in shares)	-77,000
Net income (loss)				-12,757		-12,757
Unrealized gain (loss) on investments, net of tax			-3			-3
Balance at Dec. 31, 2013	3	345,345	12	-170,269	-30,110	144,981
Balance (in shares) at Dec. 31, 2013	30,964,000					30,964,086
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options for cash and vesting of restricted stock units		4,156				4,156
Issuance of common stock upon exercise of stock options for cash and vesting of restricted stock units (in shares)	748,000
Issuance of common stock upon settlement of employee stock purchase plan		4,227				4,227
Issuance of common stock upon settlement of employee stock purchase plan (in shares)	191,000
Issuance of restricted stock to directors in lieu of fees		230				230
Issuance of restricted stock to directors in lieu of fees (in shares)	8,000
Stock-based compensation expense related to employee stock options, restricted stock units and employee stock purchase plan		16,410				16,410
Stock-based compensation expense related to consultant restricted stock units		128				128
Net income (loss)				-24,592		-24,592
Unrealized gain (loss) on investments, net of tax			-27			-27
Balance at Dec. 31, 2014	$3	$370,496	($15)	($194,861)	($30,110)	$145,513
Balance (in shares) at Dec. 31, 2014	31,911,000					31,911,901

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net income (loss)	($24,592)	($12,757)	$8,249
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	6,870	6,324	5,471
Employee stock-based compensation	16,538	17,457	15,104
Write-off of previously capitalized software costs		663
Impairment of assets held for sale and long-lived assets	375
Outside director restricted stock awarded in lieu of fees	230	230	172
Gain on disposal of property and equipment	-51		-86
Share of loss of equity method investee			98
Impairment of investments		643
Changes in assets and liabilities:
Accounts receivable	-5,470	-7,193	-1,176
Prepaid expenses and other assets	741	-1,448	-1,599
Accounts payable	985	1,238	-2,144
Accrued compensation and employee benefits	3,824	1,886	1,951
Accrued expenses and other liabilities	3,088	1,297	1,608
Deferred revenues	-251	212	-1,686
Net cash provided by operating activities	2,287	8,552	25,962
Investing activities
Purchases of property and equipment	-10,455	-11,008	-10,056
Proceeds from sale of property and equipment	122	16	206
Purchases of marketable securities	-96,800	-107,183	-103,570
Maturities of marketable securities	94,910	116,169	90,160
Purchase of other investments	-2,000	-5,000	-4,963
Net cash used in investing activities	-14,223	-7,006	-28,223
Financing activities
Net proceeds from issuance of common stock under stock plans	12,030	16,588	18,764
Withholding taxes related to restricted stock units net share settlement	-3,647	-2,845	-1,272
Repurchase of common stock		-15	-30,095
Net cash provided by (used in) financing activities	8,383	13,728	-12,603
Net (decrease) increase in cash and cash equivalents	-3,553	15,274	-14,864
Cash and cash equivalents at the beginning of the period	33,279	18,005	32,869
Cash and cash equivalents at the end of the period	29,726	33,279	18,005
Supplemental disclosure of cash flow information
Cash paid for income taxes	432	336	173
Non-cash investing and financing activities
Accrued purchase of property and equipment	$1,809	$1,138	$1,168

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Organization and Summary of Significant Accounting Policies
Organization and Summary of Significant Accounting Policies	Note 1. Organization and Summary of Significant Accounting Policies
	The Company
	Genomic Health, Inc. (the “Company”) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company develops and globally commercializes genomic‑based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company was incorporated in Delaware in August 2000. The Company’s first product, the Oncotype DX invasive breast cancer test, was launched in 2004 and is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. In January 2010, the Company launched its second product, the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (“DCIS”), a pre‑invasive form of breast cancer. This test provides a DCIS score that is used to predict the likelihood of local recurrence. In June 2012, the Company began offering the Oncotype DX colon cancer test for use in patients with stage III disease treated with oxaliplatin‑containing adjuvant therapy. In May 2013, the Company launched the Oncotype DX prostate cancer test. The test provides a Genomic Prostate Score, or GPS, to predict disease aggressiveness in men with low risk disease. This test is used to improve treatment decisions for prostate cancer patients, in conjunction with the Gleason score, or tumor grading.
	Principles of Consolidation
	These consolidated financial statements include all the accounts of the Company and its wholly‑owned subsidiaries. The Company had two wholly-owned subsidiaries at December 31, 2014: Genomic Health International Holdings, LLC, which was established in Delaware in 2010 and supports the Company’s international sales and marketing efforts; and Oncotype Laboratories, Inc., which was established in 2012, and is inactive. Genomic Health International Holdings, LLC has 10 wholly-owned subsidiaries. The functional currency for the Company’s wholly-owned subsidiaries incorporated outside the United States is the U.S. dollar. All significant intercompany balances and transactions have been eliminated.
	Basis of Presentation and Use of Estimates
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the Company’s consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.
	Certain reclassifications have been made to prior period amounts to conform to the current year presentation. For the year ended December 31, 2013, a reclassification from accrued expenses and other current liabilities was made to accrued compensation and employee benefits in the consolidated balance sheets and the accompanying consolidated statements of cash flows to conform to the current-year presentation.
	Cash Equivalents
	The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
	Marketable Securities
	The Company invests in marketable securities, primarily money market funds, obligations of U.S. Government agencies and government‑sponsored entities, corporate bonds and commercial paper. The Company considers all investments with a maturity date of less than one year as of the balance sheet date to be short‑term investments. Those investments with a maturity date greater than one year as of the balance sheet date are considered to be long‑term investments. As of December 31, 2014 and 2013, respectively, all investments in marketable securities were classified as available for sale. The Company does not intend to sell these securities and management believes it is not more likely than not that the Company will be required to sell these securities prior to the recovery of their amortized cost basis. These securities are carried at estimated fair value with unrealized gains and losses included in stockholders’ equity.
	Realized gains and losses and declines in value, if any, judged to be other than temporary on available‑for‑sale securities are reported in other income or expense. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders’ equity is reclassified out of stockholders’ equity on a specific‑identification basis and recorded in earnings for the period. The cost of securities sold is determined using specific identification.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, trade receivables and accounts payable. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, trade receivables and accounts payable, approximate fair value due to their short maturities.
	See Note 3, “Fair Value Measurements” for further information on the fair value of the Company’s financial instruments.
	Concentration of Risk
	Cash equivalents, marketable securities and trade accounts receivable are financial instruments which potentially subject the Company to concentrations of credit risk. Through December 31, 2014, no material losses had been incurred.
	The Company is subject to credit risk from its portfolio of cash equivalents and marketable securities. The Company invests in money market funds through a major U.S. bank and is exposed to credit risk in the event of default by the financial institution to the extent of amounts recorded on the consolidated balance sheets. The Company invests in short‑term, investment‑grade debt instruments and by policy limits the amount in any one type of investment, except for securities issued or guaranteed by the U.S. government. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return.
	The Company is also subject to credit risk from its accounts receivable related to its product sales. The Company performs evaluations of customers’ financial condition and generally does not require collateral. The majority of the Company’s accounts receivable arises from product sales in the United States. As of December 31, 2014, substantially all of the Company’s product revenues have been derived from sales of one product, the Oncotype DX breast cancer test. The majority of the Company’s tests to date have been delivered to physicians in the United States. All Oncotype DX tests are processed in the Company’s clinical reference laboratory facility in Redwood City, California. Medicare accounted for 20%,  21% and 22% of the Company’s product revenues for the years ended December 31, 2014, 2013 and 2012, respectively, and represented 27% and 28% of the Company’s net accounts receivable balance as of December 31, 2014 and 2013, respectively. No other third‑party payor represented more than 10% of the Company’s product revenues or accounts receivable balances for these periods.
	Allowance for Doubtful Accounts
	The Company accrues an allowance for doubtful accounts against its accounts receivable based on estimates consistent with historical payment experience. Bad debt expense is included in general and administrative expense on the Company’s consolidated statements of operations. Accounts receivable are written off against the allowance when the appeals process is exhausted, when an unfavorable coverage decision is received or when there is other substantive evidence that the account will not be paid. The Company’s allowance for doubtful accounts as of December 31, 2014 and 2013 was $3.6 million and $1.9 million, respectively. Write‑offs for doubtful accounts of $5.4 million were recorded against the allowance during each of the years ended December 31, 2014 and 2013. Bad debt expense was $6.7 million, $6.2 million, and $3.4 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Property and Equipment
	Property and equipment, including purchased software, are stated at cost. Depreciation is calculated using the straight‑line method over the estimated useful lives of the assets, which generally range from three to seven years. Leasehold improvements are amortized using the straight‑line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter.
	Intangible Assets
	Intangible assets with finite useful lives are recorded at cost, less accumulated amortization. Amortization is recognized over the estimated useful lives of the assets. The Company’s intangible assets with finite lives, which are related to patent licenses, are not material and are included in non‑current other assets on the Company’s consolidated balance sheets.
	Investments in Privately Held Companies
	The Company determines whether its investments in privately held companies are debt or equity based on their characteristics, in accordance with accounting guidance for investments. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required in accordance with accounting guidance for consolidations. If consolidation is not required and the Company owns less than 50.1% of the voting interest of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in‑substance common stock where the Company exercises significant influence over the investee, typically represented by ownership of 20% or more of the voting interests of an entity. If the equity method does not apply, investments in privately held companies determined to be equity securities are accounted for using the cost method. Investments in privately held companies determined to be debt securities are accounted for as available‑for‑sale or held‑to‑maturity securities, in accordance with accounting guidance for investments.
	In December 2010, the Company invested $500,000 in the preferred stock of a private company representing 21% of the entity’s outstanding voting shares. The Company determined that is was not the primary beneficiary of this VIE and, accordingly, applied the equity method of accounting. In June 2012, the Company invested an additional $400,000 in the preferred stock of this company as part of a new equity financing, reducing the Company’s holdings to approximately 16%. As of June 30, 2012, as a result of the Company’s ownership falling below 20% and not having the ability to exercise influence over the investee entity, the Company changed its method of accounting for this investment to the cost method. Each of the Company’s equity investments is reviewed at least annually for impairment or whenever events or changes in circumstances indicate that the carrying value of the investment might not be recoverable. At December 31, 2013, the Company concluded that the indicators of impairment of its investment in this privately held company were other than temporary and wrote off the remaining asset balance of $643,000. Therefore, the net carrying value of this investment was $0 at December 31, 2014 and 2013.
	In March 2011, the Company invested $2.3 million in the redeemable preferred stock of a private company representing 21% of the entity’s outstanding voting shares. The Company determined that the investment was a held‑to‑maturity debt security and that the investee was not subject to consolidation. In August 2012, the Company participated in the first tranche of a second preferred stock financing of this private company and purchased $1.0 million of preferred stock with no redemption privileges. In connection with this financing, the terms of the Company’s initial redeemable preferred stock investment were modified to become preferred stock with no redemption privileges. As a result of this transaction, the Company’s ownership interest was reduced to approximately 19% and the investment held by the Company is considered to be an investment in non‑marketable equity securities. In October 2012, November 2013 and August 2014, the Company participated in additional rounds of financing and purchased additional preferred stock totaling $10.6 million.  At December 31, 2014 and 2013, the Company’s ownership in this entity was approximately 8% and 12%, respectively. The investee is not consolidated because the Company owns less than 20% of the investee, and the Company does not have the ability to exercise significant influence over the investee. As a result, the Company will continue to use the cost method of accounting for this investment. The carrying value of this investment was $13.9 million at December 31, 2014 and $11.9 million at December 31, 2013, and no impairment was recognized for this investment through December 31, 2014.
	The Company’s investments in privately held companies were $13.9 million and $11.9 million at December 31, 2014 and 2013, respectively, and were included in other assets on the Company’s consolidated balance sheets.
	Impairment of Long‑lived Assets
	The Company reviews long‑lived assets, which include property and equipment, intangible assets and investments in privately held companies, for impairment whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. For property and equipment and intangible assets, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using undiscounted cash flows. For investments in non‑marketable equity securities, evidence of impairment might include the absence of an ability to recover the carrying amount of the investment or the inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment. The Company’s assessment as to whether any impairment is other than temporary is based on its ability and intent to hold the investment and whether evidence indicating the carrying value of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. If the fair value of the investment is determined to be less than the carrying value and the decline in value is considered to be other than temporary, the asset is written down to its fair value. The Company recorded impairment losses of $265,000 for equipment classified as held for sale and $110,000 for equipment disposed prior to placing it in service for the year ended December 31, 2014. There were no impairment losses for the years ended December 31, 2013 and 2012, other than the Company’s $663,000 write off of previously capitalized software costs and the $643,000 write off of an investment in a privately held company for the year ended December 31, 2013, as discussed above.
	Income Taxes
	The Company uses the liability method for income taxes, whereby deferred income taxes are provided on items recognized for financial reporting purposes over different periods than for income tax purposes. Valuation allowances are provided when the expected realization of tax assets does not meet a more‑likely‑than‑not criterion.
	The Company accounts for uncertain income tax positions using a benefit recognition model with a two‑step approach, a more‑likely‑than‑not recognition criterion and a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement, in accordance with the accounting guidance for uncertain tax positions. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. Uncertain tax positions that relate only to timing of when an item is included on a tax return are considered to have met the recognition threshold. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense when and if incurred. See Note 11, “Income Taxes” for additional information regarding unrecognized tax benefits.
	Revenue Recognition
	The Company derives its revenues from product sales and contract research arrangements. The majority of the Company’s historical product revenues have been derived from the sale of the Oncotype DX breast cancer test. The Company generally bills third‑party payors upon generation and delivery of a patient report to the physician. As such, the Company takes assignment of benefits and the risk of collection with the third‑party payor. The Company usually bills the patient directly for amounts owed after multiple requests for payment have been denied or only partially paid by the insurance carrier. The Company pursues case‑by‑case reimbursement where policies are not in place or payment history has not been established.
	The Company’s product revenues for tests performed are recognized when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Criterion (1) is satisfied when the Company has an arrangement to pay or a contract with the payor in place addressing reimbursement for the Oncotype DX test. In the absence of such arrangements, the Company considers that criterion (1) is satisfied when a third‑party payor pays the Company for the test performed. Criterion (2) is satisfied when the Company performs the test and generates and delivers to the physician, or makes available on its web portal, a patient report. When evaluating whether the fee is fixed or determinable and collectibility, we consider whether we have sufficient history to reliably estimate the total fee that will be received from a payor and a payor’s individual payment patterns.  Determination of criteria (3) and (4) are based on management’s judgments regarding whether the fee charged for products or services delivered is fixed or determinable, and the collectability of those fees under any contract or arrangement. Based upon at least several months of payment history, the Company reviews the number of tests paid against the number of tests billed and the payor’s outstanding balance for unpaid tests to determine whether payments are being made at a consistently high percentage of tests billed and at appropriate amounts given the contracted payment amount. The estimated accrual amounts per test, recorded upon delivery of a patient report, are calculated for each accrual payor and are based on the contracted price adjusted for individual payment patterns resulting from co-payment amounts and excluded services in healthcare plans. When a payment received for an individual test is either higher or lower than the estimated accrual amount, we recognize the difference as either cash revenue, in the case of higher payments, or a write off to bad debt expense, in the case of lower payments.
	To the extent all criteria set forth above are not met when test results are delivered, product revenues are recognized when cash is received from the payor.
	The Company has exclusive distribution agreements for one or more of its Oncotype DX tests with distributors covering more than 90 countries. The distributor generally provides certain marketing and administrative services to the Company within its territory. As a condition of these agreements, the distributor generally pays the Company an agreed upon fee per test and the Company processes the tests. The same revenue recognition criteria described above generally apply to tests received through distributors. To the extent all criteria set forth above are not met when test results are delivered, product revenues are generally recognized when cash is received from the distributor.
	From time to time, the Company receives requests for refunds of payments, generally due to overpayments made by third party‑payors. Upon becoming aware of a refund request, the Company establishes an accrued liability for tests covered by the refund request until such time as the Company determines whether or not a refund is due. Accrued refunds were $944,000 and $770,000 at December 31, 2014 and 2013, respectively.
	Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case‑by‑case basis according to the facts and circumstances applicable to a given contract. Under certain contracts, the Company’s input, measured in terms of full‑time equivalent level of effort or running a set of assays through its clinical reference laboratory under a contractual protocol, triggers payment obligations, and revenues are recognized as costs are incurred or assays are processed. Certain contracts have payments that are triggered as milestones are completed, such as completion of a successful set of experiments. Milestones are assessed on an individual basis and revenue is recognized when these milestones are achieved, as evidenced by acknowledgment from collaborators, provided that (1) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (2) the milestone payment is non‑refundable. Where separate milestones do not meet these criteria, the Company typically defaults to a performance‑based model, such as revenue recognition following delivery of effort as compared to an estimate of total expected effort.
	Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met.
	Cost of Product Revenues
	Cost of product revenues includes the cost of materials, direct labor, equipment and infrastructure expenses associated with processing tissue samples (including sample accessioning, histopathology, anatomical pathology, paraffin extraction, reverse transcription polymerase chain reaction (“RT‑PCR”), quality control analyses and shipping charges to transport tissue samples) and license fees. Infrastructure expenses include allocated facility occupancy and information technology costs. Costs associated with performing the Company’s tests are recorded as tests are processed. Costs recorded for tissue sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of product revenues and fixed annual payments relating to the launch and commercialization of the Company’s tests are recorded as license fees in cost of product revenues at the time product revenues are recognized or in accordance with other contractual obligations.
	Research and Development Expenses
	Research and development expenses are comprised of costs incurred to develop technology and carry out clinical studies and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, and other outside costs. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical and pharmaceutical companies. Research and development costs are expensed as incurred.
	The Company enters into collaboration and clinical trial agreements with clinical collaborators and records these costs as research and development expenses. The Company records accruals for estimated study costs comprised of work performed by its collaborators under contract terms. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are delivered or the related services are performed.
	Stock‑based Compensation
	The Company uses the Black‑Scholes option valuation model, single‑option approach, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates, to value employee stock‑based compensation at the date of grant, and recognizes stock‑ based compensation expense ratably over the requisite service period.
	Equity instruments granted to non‑employees are also valued using the Black‑Scholes option valuation model and are subject to periodic revaluation over their vesting terms. The Company did not grant any stock options to non‑employee consultants during any of the years presented.
	401(k) Plan
	Substantially all of the Company’s employees are eligible to participate in its defined contribution plan qualified under Section 401(k) of the Internal Revenue Code. The Company contributed dollar for dollar matching of employee contributions up to a maximum of $2,000,  $1,000, and $1,000 for the years ended December 31, 2014, 2013 and 2012, respectively, for each employee per year based on a full calendar year of service. The match is funded concurrently with a participant’s semi‑monthly contributions to the 401(k) Plan. The Company recorded expense for its contributions under the 401(k) Plan of $1.9 million,  $718,000 and $610,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
	Foreign Currency Transactions
	Net foreign currency transaction gains or losses are included in other income (expense), net on the Company’s consolidated statement of operations. Net foreign currency transaction losses totaled $790,000,  $158,000 and $46,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
	Comprehensive Gain or Loss
	Other comprehensive gain or loss consists of unrealized gains and losses on available‑for‑sale securities.
	Leases
	The Company enters into lease agreements for its laboratory and office facilities. These leases are classified as operating leases. Rent expense is recognized on a straight‑line basis over the term of the lease. Incentives granted under the Company’s facilities leases, including allowances to fund leasehold improvements and rent holidays, are capitalized and are recognized as reductions to rental expense on a straight‑line basis over the term of the lease.
	Guarantees and Indemnifications
	The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2014 and 2013.
	Recently Issued Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) to provide guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective in the first quarter of fiscal 2017. Early adoption is not permitted. Upon adoption, ASU 2014-09 can be applied retrospectively to all periods presented or only to the most current period presented with the cumulative effect of changes reflected in the opening balance of retained earnings in the most current period presented. The Company is currently evaluating the impact of adopting ASU 2014-09 on its consolidated financial statements.

Net_Income_Loss_Per_Share

Net Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2014
Net Income (Loss) Per Share
Net Income (Loss) Per Share	Note 2. Net Income (Loss) Per Share
	Basic net income (loss) per share is calculated by dividing net income (loss) for the period by the weighted‑average number of common shares outstanding for the period without consideration of potential common shares. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted‑ average number of common shares outstanding for the period and dilutive potential common shares for the period determined using the treasury‑stock method. The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share:
		Year Ended December 31,
		2014		2013		2012
		(In thousands except
		per share data)
	Numerator:
	Net income (loss)	$	-24,592	$	-12,757	$	8,249
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net income (loss) per share		31,453		30,512		30,326
	Effect of dilutive securities:
	Options to purchase common stock		—		—		1,704
	Restricted stock units		—		—		122
	Total		—		—		1,826
	Weighted-average shares of common stock outstanding used in the calculation of diluted net income (loss) per share		31,453		30,512		32,152
	Basic net income (loss) per share	$	-0.78	$	-0.42	$	0.27
	Diluted net income (loss) per share	$	-0.78	$	-0.42	$	0.26
	Options to purchase 1.1 million shares of the Company’s common stock and 150,000 restricted stock units were outstanding at December 31, 2014, but were not included in the computation of diluted net loss per share because their effect is anti‑dilutive. Options to purchase 1.5 million shares of the Company’s common stock and 156,000 restricted stock units were outstanding at December 31, 2013, but were not included in the computation of diluted net loss per share because their effect is anti‑dilutive. Options to purchase approximately 119,000 weighted‑average shares of the Company’s common stock were outstanding during the years ended December 31, 2012 but were not included in the computation of diluted net income per share because the options’ exercise prices were greater than the average market price of the Company’s common stock during this period; therefore, their effect is anti‑dilutive.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements
Fair Value Measurements	Note 3. Fair Value Measurements
	The Company measures certain financial assets, including cash equivalents and marketable securities, at their fair value on a recurring basis. The fair value of these financial assets was determined based on a hierarchy of three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:
	Level 1:  Quoted prices in active markets for identical assets or liabilities.
	Level 2:  Observable inputs other than Level 1 inputs, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3:  Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company did not have any non‑financial assets or liabilities that were measured or disclosed at fair value on a recurring basis at December 31, 2014 and 2013, respectively. The following tables set forth the Company’s financial instruments that were measured at fair value on a recurring basis at December 31, 2014 and 2013 by level within the fair value hierarchy:
		Actively Quoted		Significant
		Markets for		Other		Significant
		Identical		Observable		Unobservable		Balance at
		Assets		Inputs		Inputs		December 31,
		Level 1		Level 2		Level 3		2014
		(In thousands)
	As of December 31, 2014:
	Assets
	Money market deposits	$	12,397	$	—	$	—	$	12,397
	Commercial paper		—		29,749		—		29,749
	Corporate debt securities		—		46,435		—		46,435
	Total	$	12,397	$	76,184	$	—	$	88,581
		Actively Quoted		Significant
		Markets for		Other		Significant
		Identical		Observable		Unobservable		Balance at
		Assets		Inputs		Inputs		December 31,
		Level 1		Level 2		Level 3		2013
		(In thousands)
	As of December 31, 2013:
	Assets
	Money market deposits	$	15,690	$	—	$	—	$	15,690
	Commercial paper		—		37,643		—		37,643
	Corporate debt securities		—		35,428		—		35,428
	Total	$	15,690	$	73,071	$	—	$	88,761
	The Company’s debt securities of U.S. government‑sponsored entities, commercial paper and corporate bonds are classified as Level 2 as they are valued using multi‑dimensional relational pricing models that use observable market inputs, including benchmark yields, reported trades, broker‑dealer quotes, issuer spreads, benchmark securities, bids, offers and reference data. Not all inputs listed are available for use in the evaluation process on any given day for each security evaluation. In addition, market indicators and industry and economic events are monitored and may serve as a trigger to acquire further corroborating market data. There were no transfers between Level 1 and Level 2 categories during the years ended December 31, 2014 and 2013, respectively.
	All of the Company’s marketable securities are classified as available for sale. The following tables summarize the Company’s available‑for‑sale marketable securities as of the dates indicated:
		December 31, 2014
		Amortized		Unrealized		Unrealized		Estimated
		Cost		Gains		Losses		Fair Value
		(In thousands)
	Commercial paper	$	29,730	$	19	$	—	$	29,749
	Corporate debt securities		44,219		—		-34		44,185
	Total	$	73,949	$	19	$	-34	$	73,934
		December 31, 2013
		Amortized		Unrealized		Unrealized		Estimated
		Cost		Gains		Losses		Fair Value
		(In thousands)
	Commercial paper	$	36,625	$	18	$	—	$	36,643
	Corporate debt securities		35,434		3		-9		35,428
	Total	$	72,059	$	21	$	-9	$	72,071
	The Company had no realized gains or losses on its available‑for‑sale marketable securities for the years ended December 31, 2014, 2013 and 2012, respectively.
	The following table provides the breakdown of the available‑for‑sale marketable securities with unrealized losses as of the date indicated:
		In a Loss Position for
		Less Than 12 Months
		Gross
		Unrealized		Estimated
	As of December 31, 2014:	Losses		Fair Value
		(In thousands)
	Corporate debt securities	$	-34	$	42,282
	Total	$	-34	$	42,282
	All of the Company’s available‑for‑sale marketable securities had contractual maturities of one year or less as of December 31, 2014 and 2013, respectively.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property and Equipment
Property and Equipment	Note 4. Property and Equipment
	The following table summarizes the Company’s property and equipment as of the dates indicated:
		December 31,
		2014		2013
		(In thousands)
	Laboratory equipment	$	24,685	$	23,402
	Computer equipment		9,198		8,856
	Computer software—internal use		5,075		4,182
	Furniture and fixtures		3,607		3,336
	Leasehold improvements		17,902		14,886
	Work in progress		7,307		7,149
			67,774		61,811
	Less accumulated depreciation and amortization		-45,914		-43,521
	Total	$	21,860	$	18,290
	For the years ended December 31, 2014, 2013 and 2012, the Company recognized property and equipment depreciation and amortization expense of $6.7 million, $6.1 million and $5.3 million, respectively.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2014
Accrued Expenses and Other Current Liabilities
Accrued Expenses and Other Current Liabilities	Note 5. Accrued Expenses and Other Current Liabilities
	The following table summarizes the Company’s accrued expenses and other current liabilities as of the dates indicated:
		December 31,
		2014		2013
		(In thousands)
	Accrued expenses	$	4,003	$	3,610
	Accrued professional and other service fees		1,273		1,401
	Accrued refunds		944		770
	Accrued collaboration expense		2,862		908
	Accrued taxes payable		194		278
	Other current liabilities		1,168		389
	Total	$	10,444	$	7,356
	Accrued professional and other service fees include third‑party billing and collections costs, legal expenses, accounting and audit fees and investor relations expenses. Accrued refunds include overpayments due to third‑party payors.

Collaboration_and_Commercial_T

Collaboration and Commercial Technology Licensing Agreements	12 Months Ended
	Dec. 31, 2014
Collaboration and Commercial Technology Licensing Agreements
Collaboration and Commercial Technology Licensing Agreements	Note 6. Collaboration and Commercial Technology Licensing Agreements
	The Company has entered into a variety of collaboration and specimen transfer agreements relating to its development efforts. The Company recorded collaboration expenses of $6.4 million, $12.6 million and $1.9 million for the years ended December 31, 2014, 2013 and 2012, respectively, relating to services provided by the collaborators in connection with these agreements. In addition to these expenses, some of these agreements contain provisions for royalties from inventions resulting from these collaborations. The Company has specified options and rights relating to joint inventions arising out of these collaborations.
	In August 2013, the Company entered into a collaboration agreement to conduct a clinical study to validate the relationship between the Oncotype DX DCIS score and the likelihood of local recurrence in patients with DCIS. The agreement includes a study fee and milestone payments dependent on the completion of certain key milestones. As a result of the primary objective of the study being met, the Company is required to make a series of fixed future annual payments under the collaboration agreement of $604,000,  $604,000 and $504,000 in 2015, 2016 and 2017, respectively.
	In January 2014, the Company entered into a collaboration agreement to conduct a prostate study with a goal to determine the association between the Genomic Prostate Score, or GPS, provided by the assay and the likelihood of experiencing disease progression while on active surveillance.  In July 2014, the Company entered into a collaboration agreement to conduct a prostate observational study in men who choose active surveillance at one and two years after receiving the Oncotype DX prostate cancer GPS. In August 2014, the Company entered into an agreement to provide support to conduct the main phase of a prospective study dealing with individualization of adjuvant decision-making in early-stage breast cancer.  As of December 31, 2014, the estimated total remaining obligations for these agreements, including certain milestone payments, is approximately $5.2 million.  All future milestone payments are contingent on certain accomplishments, and therefore the timing for any related payments cannot be estimated.
	In November 2013, the Company entered into an exclusive license agreement to develop and commercialize a test to predict benefit from DNA damage‑based chemotherapy drugs in high risk breast cancer. The Company made an up‑front payment of $9.0 million, which was recognized in research and development expense in the fourth quarter of 2013, and will make milestone payments as certain clinical and commercial endpoints are achieved in the future. All future milestone payments are contingent on certain milestone accomplishments, and therefore the timing for future milestone payments cannot be estimated. With successful commercialization of a test, the Company will be obligated to pay royalties. In the event that the Company terminates the agreement, a break-up fee of up to $3 million will be payable and the Company will not be obligated to pay future royalty payments or the reminder of the milestone payments.
	The Company is a party to various agreements under which it licenses technology on a non‑exclusive basis in the field of human diagnostics. Access to these licenses enables the Company to process its Oncotype DX tests. While certain agreements contain provisions for fixed annual payments, license fees are generally calculated as a percentage of product revenues, with rates that vary by agreement and may be tiered, and payments that may be capped at annual minimum or maximum amounts. The Company recognized costs recorded under these agreements totaling $9.5 million, $8.9 million and $8.0 million for the years ended December 31, 2014, 2013 and 2012, respectively, which were included in cost of product revenues.
	At December 31, 2014, fixed future annual payments, exclusive of royalty payments, relating to the launch and commercialization of the Oncotype DX colon cancer test and the Oncotype DX prostate cancer test totaled $550,000 and are fully payable in 2015. These payments are recorded in cost of product revenues as license fees. If at any time the Company discontinues the sale of the products covered by the agreement, no future annual payments will be payable and the Company will have no further obligation under the applicable agreement.
	Contract Research Arrangements
	In November 2007, the Company entered into a Collaborative Diagnostic Development Agreement with Pfizer Inc. to provide research and development services for the development of a diagnostic product for renal cell cancer. The Company received an initial payment of $1.5 million and was initially eligible to receive a payment of $2.2 million upon joint agreement on a gene identification plan, $5.0 million in additional payments upon the earlier of Pfizer’s election to initiate the next phase of development or a specified number of months from the date the Company received the sample set and related clinical data necessary to conduct the first phase of development, and a final payment of $1.5 million upon completion of clinical validation. Completion of clinical validation represents a substantive milestone and the Company recognized the $1.5 million payment upon completion in December 2013. All other payments were not considered substantive milestones as they are not based solely on the Company’s past performance. Such payments were recognized using a performance‑based model and revenue is recognized following delivery of effort as compared to an estimate of total expected effort. The Company did not recognize any revenue related to substantive milestones under this arrangement during the years ended December 31, 2014 and 2013.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2014
Commitments
Commitments	Note 7. Commitments
	Lease Obligations
	In September 2005, the Company entered into a non‑cancelable lease for 48,000 square feet of laboratory and office space that the Company currently occupies in Redwood City, California. In November 2010, the Company executed an amendment to extend the term of the lease through March 2019, with an option for the Company to extend the term of the lease for an additional five years. The agreement included lease incentive obligations of $834,000 that are being amortized on a straight‑line basis over the life of the lease.
	In January 2007, the Company entered into a non‑cancelable lease for an additional 48,000 square feet of laboratory and office space in a nearby location. In November 2010, the Company executed an amendment to extend the term of the lease through March 2018, with an option for the Company to extend the lease for an additional five years. The agreement included lease incentive obligations totaling $283,000 that are being amortized on a straight‑line basis over the life of the lease.
	In October 2009, the Company entered into a non‑cancelable agreement to lease an additional 30,500 square feet of office space near the locations the Company occupied. The lease expires in March 2018, with an option for the Company to extend the term of the lease for an additional five years. The agreement includes lease incentive obligations of $307,000 that are being amortized on a straight‑line basis over the life of the lease.
	In August 2013, the Company entered into a non‑cancelable agreement to lease an additional 18,400 square feet of laboratory and office space near the locations the Company currently occupies. The lease expires in March 2019, with an option for the Company to extend the term of the lease for an additional five years. In July 2014, the Company leased an additional 5,500 square feet in the same location on the same terms. The agreements include lease incentive obligations of $358,000 which are being amortized on a straight line basis over the life of the lease.
	In May 2010, the Company’s European subsidiary entered into a non‑cancelable lease for approximately 2,500 square feet of office space in Geneva, Switzerland. In May 2014, the Company executed an amendment to extend the terms of the lease and executed a new lease for approximately 5,000 square feet of additional space in the same location. Both lease agreements expire in May 2016. Additionally, the Company has offices in France, Germany, Ireland, Italy, Japan and the United Kingdom with short term rental agreements.
	Rent expense under all operating leases amounted to $3.7 million, $3.0 million and $3.7 million for the years ended December 31, 2014, 2013 and 2012, respectively. Future non‑cancelable commitments under these operating leases at December 31, 2014 were as follows:
		Annual
		Payments
		(In thousands)
	Years Ending December 31,
	2015	$	3,928
	2016		3,872
	2017		3,867
	2018		2,476
	2019		504
	Total minimum payments	$	14,647

Capital_Stock

Capital Stock	12 Months Ended
	Dec. 31, 2014
Capital Stock
Capital Stock	Note 8. Capital Stock
	Common Stock
	As of December 31, 2014, the Company had 31,911,901 shares of common stock outstanding. Shares of common stock reserved for future issuance as of December 31, 2014 were as follows:
		Number of
		Shares
		(In thousands)
	Shares to be issued upon exercise of outstanding stock options and vesting of restricted stock units (RSUs)	4,420
	Shares available for future stock option and RSU grants, settlement of employee stock purchase plan (ESPP) and restricted stock to be issued to outside directors in lieu of director fees	1,746
	Shares of common stock reserved for future issuance	6,166
	Treasury Stock
	In December 2012, the Company entered into an accelerated share repurchase agreement with a financial institution to repurchase $30.0 million of its common stock on an accelerated basis. Under the terms of this accelerated share repurchase agreement, the Company paid $30.0 million to the financial institution to settle the initial purchase transaction and received 984,074 shares of its common stock, representing the minimum number of shares deliverable under the agreement. In February 2013, upon termination of the agreement and in accordance with the share delivery provisions of the agreement, the Company received an additional 77,257 shares of its common stock based on the average of the daily volume weighted‑average prices of its common stock during a specified period less a predetermined discount per share. As a result, the average purchase price of the Company’s common stock from the accelerated share repurchase program was $28.27 per share.
	The Company accounted for the accelerated share repurchase as two separate transactions: (a) as shares of common stock acquired in a treasury stock transaction recorded on the transaction date and (b) as a forward contract indexed to the Company’s common stock. As such, the 984,074 shares repurchased were accounted for as a repurchase of common stock. The 77,257 additional shares that the Company received upon termination of the contract in February 2013 were also recorded in stockholders’ equity. The Company determined that the forward contract indexed to the Company’s common stock met all of the applicable criteria for equity classification, and therefore, the contract was not accounted for as a derivative.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Stock-Based Compensation
Stock-Based Compensation	Note 9. Stock‑based Compensation
	2005 Stock Incentive Plan
	On September 8, 2005, the Board of Directors approved the 2005 Stock Incentive Plan (the “2005 Plan”), which was later approved by the Company’s stockholders. Pursuant to the 2005 Plan, stock options, restricted shares, stock units, including RSUs, and stock appreciation rights may be granted to employees, consultants, and outside directors of the Company. Options granted may be either incentive stock options or nonstatutory stock options. The Company initially reserved 5,000,000 shares of the Company’s common stock for issuance under the 2005 Plan, effective upon the closing of the Company’s initial public offering on October 4, 2005. On June 8, 2009, the Company’s stockholders approved an amendment to the 2005 Plan to increase the shares reserved for issuance under the 2005 Plan by 3,980,000 shares. The amended and restated plan also extends the term under which awards may be granted under the 2005 Plan until January 27, 2019. As of December 31, 2014, options to purchase 985,722 shares of common stock were available for future grant under the 2005 Plan.
	Stock options are governed by stock option agreements between the Company and recipients of stock options. Incentive stock options may be granted under the 2005 Plan at an exercise price of not less than 100% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Nonstatutory stock options may be granted under the 2005 Plan at an exercise price of not less than 80% of the fair market value of the common stock on the date of grant, determined by the Compensation Committee of the Board of Directors. Options become exercisable and expire as determined by the Compensation Committee, provided that the term of incentive stock options may not exceed 10 years from the date of grant. Stock option agreements may provide for accelerated exercisability in the event of an optionee’s death, disability, or retirement or other events.
	Under the 2005 Plan, each outside director who joins the board after the effective date of the 2005 Plan will receive an automatic nonstatutory stock option grant that vests at a rate of 25% at the end of the first year, with the remaining balance vesting monthly over the next three years. On the first business day following the annual meeting of the Company’s stockholders, each outside director who is continuing board service and who was not initially elected to the board at the annual meeting will receive an additional nonstatutory stock option grant, which will vest in full on the first anniversary of the date of grant or, if earlier, immediately prior to the next annual meeting of the Company’s stockholders. Nonstatutory stock options granted to outside directors must have an exercise price equal to 100% of the fair market value of the common stock on the date of grant. Nonstatutory stock options terminate on the earlier of the day before the tenth anniversary of the date of grant or the date twelve months after termination of the outside director’s service as a member of the Board of Directors.
	In 2011, the Compensation Committee of the Board of Directors revised the Company’s equity incentive guidelines. Under the revised guidelines, most employees receive grants of RSUs in lieu of stock options. Employees with titles of vice president and above are eligible to receive stock options and RSUs. The target percentages of equity grant value for employees with titles of vice president and above other than our executive officers are 50% stock options and 50% RSUs, and the target percentages for executive officers are 75% stock options and 25% RSUs. The RSUs generally vest in three equal annual installments. As of April 2011, outside directors were given the option to elect to receive some or all of their retainers (other than retainers for serving as committee chair) in the form of fully‑vested restricted stock. Restricted shares, stock units and stock appreciation rights granted under the 2005 Plan are governed by agreements between the Company and recipients of the awards. Terms of the agreements are determined by the Compensation Committee.
	In March 2014, the Company approved awards of performance-based restricted stock units (“PVRSUs”) for certain senior officers under the 2005 Plan, as amended and restated by the Board of Directors on March 24, 2014. The awards were subject to approval of the amended and restated plan by the Company’s stockholders, which was approved at the June 2014 Annual Meeting. In order for the senior officers to be eligible to earn any of the PVRSUs, the Company must achieve certain corporate-level objectives. The amount potentially available under a PVRSU is subject to the attainment of pre-established, objective performance goals over a specified period. The PVRSUs vest based on achievement of three performance milestones, not to exceed 100% in the aggregate: a revenue milestone, weighted from 0% to 100%; a tests delivered milestone, weighted from 0% to 100%; and a reimbursement-related milestone, weighted from 0% to 33 1/3%. In addition, the awards also have a service vesting criteria following the achievement of performance criteria through February 2016. As of December 31, 2014, there were 13,533 PVRSUs outstanding with a grant date fair value of $368,000.
	The Company recognizes the fair value of these awards to the extent the achievement of the related performance criteria is estimated to be probable. If a performance criteria is subsequently determined to not be probable of achievement, any related expense is reversed in the period such determination is made. Conversely, if a performance criteria is not currently expected to be achieved but is later determined to be probable of achievement, a “catch-up” entry is recorded in the period such determination is made for the expense that would have been recognized had the performance criteria been probable of achievement since the grant of the award.
	Employee Stock Purchase Plan
	In June 2011, the Company’s stockholders approved the Company’s Employee Stock Purchase Plan (“ESPP”). The ESPP provides eligible employees with an opportunity to purchase common stock from the Company and to pay for their purchases through payroll deductions. The ESPP is implemented through a series of offerings of purchase rights to eligible employees beginning December 1, 2011. Under the ESPP, the Compensation Committee of the Company’s Board of Directors may specify offerings with a duration of not more than 27 months, and may specify shorter purchase periods within each offering. During each purchase period, payroll deductions accumulate without interest. On the last day of the purchase period, accumulated payroll deductions are used to purchase common stock for employees participating in the offering. The purchase price is specified pursuant to the offering, but cannot, under the terms of the ESPP, be less than 85% of the fair market value per share of the Company’s common stock on either the last trading day preceding the offering date or on the purchase date, whichever is less.
	The Company’s Board of Directors has determined that the purchase periods initially shall have a duration of six months and that the purchase price will be 85% of the fair market value per share of the Company’s common stock on either the last trading day preceding the offering date or the purchase date, whichever is less. The length of the purchase period applicable to U.S. employees and the purchase price may not be changed without the approval of the independent members of the Company’s Board of Directors.
	During 2014, 191,318 shares were issued under the ESPP. A total of 1,250,000 shares of common stock have been reserved for issuance under the ESPP, of which 759,738 shares were available for issuance as of December 31, 2014. During 2013 and 2012, 152,881 and 146,063 shares were issued under the ESPP, respectively.
	As of December 31, 2014, there was $592,000 of unrecognized compensation expense related to the ESPP, which is expected to be recognized over a period of five months.
	Stock Option Activity
	The following table summarizes option activity for the year ended December 31, 2014:
							Weighted-Average
		Outstanding Options					Remaining		Aggregate
		Number of		Weighted-Average			Contractual		Intrinsic
		Shares		Exercise Price			Life		Value
		(In thousands)		(In years)					(In thousands)
	Balance at December 31, 2013	4,109		$	20.57
	Options granted	442		$	30.35
	Options exercised	-553		$	14.11
	Options forfeited	-221		$	30.18
	Balance at December 31, 2014	3,777		$	22.10		5.1		$	37,768
	Exercisable at December 31, 2014	3,119		$	20.45		4.3		$	36,327
	Vested and expected to vest at December 31, 2014	3,729		$	21.99		5.0		$	37,681
	The total intrinsic value of stock options exercised during the years ended December 31, 2014, 2013 and 2012 was $8.2 million, $13.5 million and $15.3 million, respectively. The total fair value of stock options vested during the years ended December 31, 2014, 2013 and 2012 was $6.0 million, $7.3 million and $7.9 million, respectively.
	Restricted Stock Unit Activity
	A following table summarizes RSU activity for the year ended December 31, 2014:
				Weighted-Average
		Number of		Grant Date Fair
		Shares		Value
		(In thousands)
	Balance at December 31, 2013	681		$	29.46
	RSUs granted	383		$	29.05
	RSUs vested	-327		$	28.25
	RSUs cancelled	-107		$	30.54
	Balance at December 31, 2014	630		$	29.65
	The weighted-average per share grant date fair values of RSUs granted were $29.05,  $30.56 and $29.81 during the years ended December 31, 2014, 2013 and 2012, respectively.  The fair value of RSUs as of their respective vesting dates were $9.1 million and $6.9 million for the year ended December 31, 2014 and 2013, respectively. There were no RSUs vested prior to 2012.
	Performance-Based Restricted Stock Unit Activity
	A following table summarizes PVRSU activity for the year ended December 31, 2014:
				Weighted-Average
		Number of		Grant Date Fair
		Shares		Value
		(In thousands)
	Balance at December 31, 2013	—		$	—
	PVRSUs granted	14		$	27.21
	PVRSUs vested	—		$	—
	PVRSUs cancelled	—		$	—
	Balance at December 31, 2014	14		$	27.21
	There were no PVRSUs vested during 2014 and no PVRSUs granted prior to 2014.
	Restricted Stock in Lieu of Directors’ Fees
	Outside members of the Company’s Board of Directors may elect to receive fully‑vested restricted stock in lieu of cash compensation for services as a director. During the years ended December 31, 2014, 2013 and 2012, the Company issued 8,209,  7,769, and 5,512 shares of restricted stock, respectively, to outside directors, with vesting date fair values of $230,000,  $230,000, and $172,000, respectively, and a weighted‑average grant date fair value of $27.97,  $29.54, and $30.79 per share, respectively.
	Employee Stock‑Based Compensation Expense
	The stock-based compensation is recognized as expense over the requisite service periods in our Consolidated Statement of Operations using the straight-line expense attribution approach for stock options and RSUs, and using a graded vesting expense attribution approach for PVRSUs. The Company recognized employee stock‑based compensation expense of $16.5 million, $17.5 million and $15.1 million for the years ended December 31, 2014, 2013 and 2012, respectively. Employee stock‑based compensation expense was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Employee stock‑based compensation expense includes expense related to stock options granted to outside directors of the Company as well as stock purchased under the ESPP. The following table presents the impact of employee stock‑based compensation expense on selected statement of operations line items for the periods indicated:
		Year Ended December 31,
		2014			2013			2012
		(In thousands)
	Cost of product revenues	$	497		$	483		$	441
	Research and development		4,569			4,873			3,992
	Selling and marketing		4,396			4,369			4,191
	General and administrative		7,076			7,732			6,480
	Total	$	16,538		$	17,457		$	15,104
As of December 31, 2014, unrecognized compensation expense related to unvested stock options, RSUs and PVRSUs, net of estimated forfeitures, were $6.4 million, $10.7 million and $146,000, respectively. The Company expects to recognize these expenses over a weighted‑average period of 2.4 years, 1.8 years, and 0.9 year, respectively.
Valuation Assumptions
Fair values of awards granted under the 2005 Plan and ESPP were estimated at grant or purchase dates using a Black‑Scholes option valuation model. Option valuation models require the input of highly subjective assumptions that can vary over time. The Company’s assumptions regarding expected volatility are based on the historical volatility of the Company’s common stock. The expected life of options granted is estimated based on historical option exercise data and assumptions related to unsettled options. The risk‑free interest rate is estimated using published rates for U.S. Treasury securities with a remaining term approximating the expected life of the options granted. The Company uses a dividend yield of zero as it has never paid cash dividends and does not anticipate paying cash dividends in the foreseeable future. The weighted‑average fair values and assumptions used in calculating such values during each fiscal year are as follows:
	Year Ended December 31,
	2014			2013			2012
Expected volatility:
Stock options		44	%		46	%		46	%
ESPP		37	%		39	%		43	%
Risk-free interest rate:
Stock options		1.97	%		1.40	%		1.23	%
ESPP		0.08	%		0.11	%		0.09	%
Expected life in years:
Stock options		6.61			6.64			6.98
ESPP		0.50			0.50			0.50
Weighted-average fair value:
Stock options	$	14.13		$	14.11		$	14.51
ESPP	$	7.24		$	7.82			7.67

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Information
Segment Information	Note 10. Segment Information
	The Company operates in one business segment, which primarily focuses on the development and global commercialization of genomic‑based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The Company’s Oncotype DX breast and colon tests have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. As of December 31, 2014, the majority of the Company’s product revenues have been derived from sales of one product, the Oncotype DX breast cancer test.
	As of December 31, 2014, the majority of the Company’s tests have been delivered to physicians in the United States. All Oncotype DX tests are processed in the Company’s clinical reference laboratory facility in Redwood City, California. The following table summarizes total revenues from customers, payors and collaboration partners by geographic region (in thousands). Product revenues are attributed to countries based on ship‑to location. Contract revenues are attributed to countries based on the location of the collaboration partner.
		Year Ended December 31,
		2014		2013		2012
		(In thousands)
	United States	$	230,657	$	223,662	$	207,508
	Outside of the United States		45,049		37,933		27,665
	Total revenues	$	275,706	$	261,595	$	235,173

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes
Income Taxes
	Note 11. Income Taxes
	The components of the Company’s income (loss) before income taxes were as follows:
		Year Ended December 31,
		2014		2013		2012
		(In thousands)
	Domestic	$	-25,337	$	-13,294	$	8,018
	Foreign		1,138		883		653
	Total income (loss) before income taxes	$	-24,199	$	-12,411	$	8,671
	The components of the Company’s income tax expense (benefit) were as follows:
		Year Ended
		December 31,
		2014		2013		2012
		(In thousands)
	Current expense (benefit):
	Federal	$	—	$	-22	$	111
	State		40		57		99
	Foreign		353		311		212
	Total income tax expense	$	393	$	346	$	422
	The income tax expense (benefit) differs from the amount computed by applying the statutory federal income tax rate as follows:
		Year Ended December 31,
		2014		2013		2012
		(In thousands)
	Federal tax at statutory rate	$	-8,470	$	-4,344	$	3,035
	Non-deductible officer compensation		79		—		—
	Stock-based compensation		789		1,149		1,659
	Non-deductible meals and entertainment		531		507		492
	Net operating losses not used (used)		7,478		2,999		-4,973
	Federal alternative minimum tax		—		—		120
	State tax, net of federal benefit		26		37		64
	Other		-40		-2		25
	Total income tax expense	$	393	$	346	$	422
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred tax assets and liabilities are as follows:
		December 31,
		2014		2013
		(In thousands)
	Deferred tax assets:
	Net operating loss carryforwards	$	35,060	$	30,970
	Stock-based compensation		10,210		9,150
	Research tax credits		12,500		9,580
	Fixed assets		3,520		3,200
	Capitalized costs		3,590		3,860
	Other		6,890		5,080
	Total deferred tax assets		71,770		61,840
	Valuation allowance		-71,770		-61,840
	Net deferred tax assets	$	—	$	—
	Based on all available objective evidence, the Company believes that it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company recorded a valuation allowance against all of its net deferred tax assets for the years ended December 31, 2014 and 2013, respectively. The Company will continue to maintain a full valuation allowance on its deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of this allowance. The net valuation allowance increased by $9.9 million and $7.2 million, and decreased by $3.8 million during the years ended December 31, 2014, 2013 and 2012, respectively.
	As of December 31, 2014, the Company had federal and state net operating loss carryforwards of approximately $115.0 million and $86.0 million, respectively, and federal and state research and development tax credit carryforwards of approximately $9.3 million and $6.7 million, respectively. The federal net operating loss and federal tax credit carryforwards will expire at various dates beginning in 2021. The state net operating loss carryforwards begin to expire in 2015 if not utilized. The state tax credit carryforwards have no expiration date. None of the net operating loss and tax credit carryforwards are subject to the limitations imposed by Sections 382 and 383 of the Internal Revenue Code.
	The Company tracks a portion of its deferred tax assets attributable to stock option benefits in a separate memorandum account. Therefore, these amounts are not included in the Company’s gross or net deferred tax assets. The benefit of these stock options will not be recorded in equity unless it reduces taxes payable. As of December 31, 2014, the portion of the federal and state net operating losses related to stock option benefits was approximately $27.9 million.
	The Company had $1.6 million, $2.2 million and $875,000 of unrecognized tax benefits as of December 31, 2014, 2013 and 2012, respectively. The unrecognized tax benefits are primarily research tax credits for all years. The following table summarizes the activity related to unrecognized tax benefits:
		Year Ended
		December 31,
		2014		2013		2012
		(In thousands)
	Balance at January 1	$	2,160	$	875	$	839
	Increase (decrease) related to prior year tax positions		-907		74		-3
	Increase related to current year tax positions		347		1,211		39
	Balance at December 31	$	1,600	$	2,160	$	875
	Unrecognized tax benefits may change during the next twelve months for items that arise in the ordinary course of business. The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company’s effective tax rate.
	Accrued interest and penalties related to unrecognized tax benefits are recognized as part of the Company’s income tax provision in its consolidated statement of operations. For the year ended December 31, 2014, 2013 and 2012, the Company recognized $6,400,  $5,700 and $6,800 in interest and penalties, respectively, related to unrecognized tax benefits.
	The Company files federal, state and foreign income tax returns in many jurisdictions in the United States and abroad. The statute of limitations remain open for fiscal 2000 through 2014 in U.S. federal and state jurisdictions, and for fiscal 2010 through 2014 in foreign jurisdictions. Fiscal years outside the normal statute of limitations remain open to audit by tax authorities due to tax attributes generated in early years which have been carried forward and may be audited in subsequent years when utilized.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data (Unaudited)	Note 12. Selected Quarterly Financial Data (Unaudited)
	The following table contains selected unaudited consolidated statement of operations information for each of the fiscal quarters in 2014 and 2013. The Company believes that the following information reflects all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.
	Quarter Ended	March 31,		June 30,		September 30,		December 31,
		(In thousands, except per share data)
	2014:00:00
	Total revenues	$	67,002	$	70,477	$	69,101	$	69,126
	Product revenues		67,002		70,477		69,101		69,126
	Cost of product revenues		12,055		12,207		11,979		12,501
	Net loss		-7,445		-4,618		-6,262		-6,267
	Basic and diluted net loss per common share	$	-0.24	$	-0.15	$	-0.2	$	-0.2
	2013:00:00
	Total revenues	$	63,094	$	63,691	$	65,990	$	68,819
	Product revenues		62,709		63,691		65,732		67,060
	Cost of product revenues		9,746		10,757		10,781		10,815
	Net income (loss)		-883		-2,994		488		-9,369
	Basic net income (loss) per common share	$	-0.03	$	-0.1	$	0.02	$	-0.3
	Diluted net income (loss) per common share	$	-0.03	$	-0.1	$	0.02	$	-0.3
	The quarterly increases in product revenues during 2014 and 2013 were primarily attributable to increased adoption of the Oncotype DX breast and colon cancer tests by physicians, international expansion, increased revenues recorded on an accrual basis, and increased reimbursement for these tests by third‑party payors. The increase in cost of product revenues during 2014 and 2013 was primarily due to incremental costs related to test processing associated with the launch of the Oncotype DX prostate cancer test and enhancements to the Company’s laboratory information management system, as well as a milestone license fee paid in connection with the launch of the Company’s prostate cancer test in May 2013. The net loss for the quarter ended December 31, 2013 was primarily due to an up‑front payment of $9.0 million under a license agreement. Per share amounts for the quarters and full year have been calculated separately. Accordingly, quarterly amounts may not add up to the annual amount because of differences in the weighted‑average common shares outstanding during each period, due primarily to the effect of the Company’s issuing shares of its common stock during the year.
	For all of the quarters in 2014 and the quarters ended March 31, June 30 and December 31, 2013, basic and diluted net loss per common share were identical as potential common shares were excluded from the calculation because their effects were anti‑dilutive.

SCHEDULE_II_VALUATION_AND_QUAL

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2014
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	SCHEDULE II
	GENOMIC HEALTH, INC.
	VALUATION AND QUALIFYING ACCOUNTS
	Years Ended December 31, 2014, 2013 and 2012
		Balance at						Balance at
		Beginning of						End of
		Period		Expenses		Deductions		Period
		(In thousands)
	Allowance for Doubtful Accounts:
	Year ended December 31, 2014	$	1,907	$	7,104	$	5,383	$	3,628
	Year ended December 31, 2013	$	1,133	$	6,169	$	5,395	$	1,907
	Year ended December 31, 2012	$	1,206	$	3,408	$	3,481	$	1,133

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Organization and Summary of Significant Accounting Policies
Principles of Consolidation	Principles of Consolidation
	These consolidated financial statements include all the accounts of the Company and its wholly‑owned subsidiaries. The Company had two wholly-owned subsidiaries at December 31, 2014: Genomic Health International Holdings, LLC, which was established in Delaware in 2010 and supports the Company’s international sales and marketing efforts; and Oncotype Laboratories, Inc., which was established in 2012, and is inactive. Genomic Health International Holdings, LLC has 10 wholly-owned subsidiaries. The functional currency for the Company’s wholly-owned subsidiaries incorporated outside the United States is the U.S. dollar. All significant intercompany balances and transactions have been eliminated.
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the Company’s consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates.
	Certain reclassifications have been made to prior period amounts to conform to the current year presentation. For the year ended December 31, 2013, a reclassification from accrued expenses and other current liabilities was made to accrued compensation and employee benefits in the consolidated balance sheets and the accompanying consolidated statements of cash flows to conform to the current-year presentation.
Cash Equivalents	Cash Equivalents
	The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Marketable Securities	Marketable Securities
	The Company invests in marketable securities, primarily money market funds, obligations of U.S. Government agencies and government‑sponsored entities, corporate bonds and commercial paper. The Company considers all investments with a maturity date of less than one year as of the balance sheet date to be short‑term investments. Those investments with a maturity date greater than one year as of the balance sheet date are considered to be long‑term investments. As of December 31, 2014 and 2013, respectively, all investments in marketable securities were classified as available for sale. The Company does not intend to sell these securities and management believes it is not more likely than not that the Company will be required to sell these securities prior to the recovery of their amortized cost basis. These securities are carried at estimated fair value with unrealized gains and losses included in stockholders’ equity.
	Realized gains and losses and declines in value, if any, judged to be other than temporary on available‑for‑sale securities are reported in other income or expense. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders’ equity is reclassified out of stockholders’ equity on a specific‑identification basis and recorded in earnings for the period. The cost of securities sold is determined using specific identification.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company’s financial instruments consist principally of cash and cash equivalents, marketable securities, trade receivables and accounts payable. The carrying amounts of certain of these financial instruments, including cash and cash equivalents, trade receivables and accounts payable, approximate fair value due to their short maturities.
	See Note 3, “Fair Value Measurements” for further information on the fair value of the Company’s financial instruments.
Concentration of Risk	Concentration of Risk
	Cash equivalents, marketable securities and trade accounts receivable are financial instruments which potentially subject the Company to concentrations of credit risk. Through December 31, 2014, no material losses had been incurred.
	The Company is subject to credit risk from its portfolio of cash equivalents and marketable securities. The Company invests in money market funds through a major U.S. bank and is exposed to credit risk in the event of default by the financial institution to the extent of amounts recorded on the consolidated balance sheets. The Company invests in short‑term, investment‑grade debt instruments and by policy limits the amount in any one type of investment, except for securities issued or guaranteed by the U.S. government. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return.
	The Company is also subject to credit risk from its accounts receivable related to its product sales. The Company performs evaluations of customers’ financial condition and generally does not require collateral. The majority of the Company’s accounts receivable arises from product sales in the United States. As of December 31, 2014, substantially all of the Company’s product revenues have been derived from sales of one product, the Oncotype DX breast cancer test. The majority of the Company’s tests to date have been delivered to physicians in the United States. All Oncotype DX tests are processed in the Company’s clinical reference laboratory facility in Redwood City, California. Medicare accounted for 20%,  21% and 22% of the Company’s product revenues for the years ended December 31, 2014, 2013 and 2012, respectively, and represented 27% and 28% of the Company’s net accounts receivable balance as of December 31, 2014 and 2013, respectively. No other third‑party payor represented more than 10% of the Company’s product revenues or accounts receivable balances for these periods.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts
	The Company accrues an allowance for doubtful accounts against its accounts receivable based on estimates consistent with historical payment experience. Bad debt expense is included in general and administrative expense on the Company’s consolidated statements of operations. Accounts receivable are written off against the allowance when the appeals process is exhausted, when an unfavorable coverage decision is received or when there is other substantive evidence that the account will not be paid. The Company’s allowance for doubtful accounts as of December 31, 2014 and 2013 was $3.6 million and $1.9 million, respectively. Write‑offs for doubtful accounts of $5.4 million were recorded against the allowance during each of the years ended December 31, 2014 and 2013. Bad debt expense was $6.7 million, $6.2 million, and $3.4 million for the years ended December 31, 2014, 2013 and 2012, respectively.
Property and Equipment	Property and Equipment
	Property and equipment, including purchased software, are stated at cost. Depreciation is calculated using the straight‑line method over the estimated useful lives of the assets, which generally range from three to seven years. Leasehold improvements are amortized using the straight‑line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter.
Intangible Assets	Intangible Assets
	Intangible assets with finite useful lives are recorded at cost, less accumulated amortization. Amortization is recognized over the estimated useful lives of the assets. The Company’s intangible assets with finite lives, which are related to patent licenses, are not material and are included in non‑current other assets on the Company’s consolidated balance sheets.
Investments in Privately Held Companies	Investments in Privately Held Companies
	The Company determines whether its investments in privately held companies are debt or equity based on their characteristics, in accordance with accounting guidance for investments. The Company also evaluates the investee to determine if the entity is a variable interest entity (“VIE”) and, if so, whether the Company is the primary beneficiary of the VIE, in order to determine whether consolidation of the VIE is required in accordance with accounting guidance for consolidations. If consolidation is not required and the Company owns less than 50.1% of the voting interest of the entity, the investment is evaluated to determine if the equity method of accounting should be applied. The equity method applies to investments in common stock or in‑substance common stock where the Company exercises significant influence over the investee, typically represented by ownership of 20% or more of the voting interests of an entity. If the equity method does not apply, investments in privately held companies determined to be equity securities are accounted for using the cost method. Investments in privately held companies determined to be debt securities are accounted for as available‑for‑sale or held‑to‑maturity securities, in accordance with accounting guidance for investments.
	In December 2010, the Company invested $500,000 in the preferred stock of a private company representing 21% of the entity’s outstanding voting shares. The Company determined that is was not the primary beneficiary of this VIE and, accordingly, applied the equity method of accounting. In June 2012, the Company invested an additional $400,000 in the preferred stock of this company as part of a new equity financing, reducing the Company’s holdings to approximately 16%. As of June 30, 2012, as a result of the Company’s ownership falling below 20% and not having the ability to exercise influence over the investee entity, the Company changed its method of accounting for this investment to the cost method. Each of the Company’s equity investments is reviewed at least annually for impairment or whenever events or changes in circumstances indicate that the carrying value of the investment might not be recoverable. At December 31, 2013, the Company concluded that the indicators of impairment of its investment in this privately held company were other than temporary and wrote off the remaining asset balance of $643,000. Therefore, the net carrying value of this investment was $0 at December 31, 2014 and 2013.
	In March 2011, the Company invested $2.3 million in the redeemable preferred stock of a private company representing 21% of the entity’s outstanding voting shares. The Company determined that the investment was a held‑to‑maturity debt security and that the investee was not subject to consolidation. In August 2012, the Company participated in the first tranche of a second preferred stock financing of this private company and purchased $1.0 million of preferred stock with no redemption privileges. In connection with this financing, the terms of the Company’s initial redeemable preferred stock investment were modified to become preferred stock with no redemption privileges. As a result of this transaction, the Company’s ownership interest was reduced to approximately 19% and the investment held by the Company is considered to be an investment in non‑marketable equity securities. In October 2012, November 2013 and August 2014, the Company participated in additional rounds of financing and purchased additional preferred stock totaling $10.6 million.  At December 31, 2014 and 2013, the Company’s ownership in this entity was approximately 8% and 12%, respectively. The investee is not consolidated because the Company owns less than 20% of the investee, and the Company does not have the ability to exercise significant influence over the investee. As a result, the Company will continue to use the cost method of accounting for this investment. The carrying value of this investment was $13.9 million at December 31, 2014 and $11.9 million at December 31, 2013, and no impairment was recognized for this investment through December 31, 2014.
	The Company’s investments in privately held companies were $13.9 million and $11.9 million at December 31, 2014 and 2013, respectively, and were included in other assets on the Company’s consolidated balance sheets.
Impairment of Long-lived Assets	Impairment of Long‑lived Assets
	The Company reviews long‑lived assets, which include property and equipment, intangible assets and investments in privately held companies, for impairment whenever events or changes in business circumstances indicate that the carrying amounts of the assets may not be fully recoverable. For property and equipment and intangible assets, an impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is assessed using undiscounted cash flows. For investments in non‑marketable equity securities, evidence of impairment might include the absence of an ability to recover the carrying amount of the investment or the inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment. The Company’s assessment as to whether any impairment is other than temporary is based on its ability and intent to hold the investment and whether evidence indicating the carrying value of the investment is recoverable within a reasonable period of time outweighs evidence to the contrary. If the fair value of the investment is determined to be less than the carrying value and the decline in value is considered to be other than temporary, the asset is written down to its fair value. The Company recorded impairment losses of $265,000 for equipment classified as held for sale and $110,000 for equipment disposed prior to placing it in service for the year ended December 31, 2014. There were no impairment losses for the years ended December 31, 2013 and 2012, other than the Company’s $663,000 write off of previously capitalized software costs and the $643,000 write off of an investment in a privately held company for the year ended December 31, 2013, as discussed above.
Income Taxes	Income Taxes
	The Company uses the liability method for income taxes, whereby deferred income taxes are provided on items recognized for financial reporting purposes over different periods than for income tax purposes. Valuation allowances are provided when the expected realization of tax assets does not meet a more‑likely‑than‑not criterion.
	The Company accounts for uncertain income tax positions using a benefit recognition model with a two‑step approach, a more‑likely‑than‑not recognition criterion and a measurement attribute that measures the position as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement, in accordance with the accounting guidance for uncertain tax positions. If it is not more likely than not that the benefit will be sustained on its technical merits, no benefit is recorded. Uncertain tax positions that relate only to timing of when an item is included on a tax return are considered to have met the recognition threshold. The Company recognizes accrued interest and penalties related to unrecognized tax benefits in income tax expense when and if incurred. See Note 11, “Income Taxes” for additional information regarding unrecognized tax benefits.
Revenue Recognition	Revenue Recognition
	The Company derives its revenues from product sales and contract research arrangements. The majority of the Company’s historical product revenues have been derived from the sale of the Oncotype DX breast cancer test. The Company generally bills third‑party payors upon generation and delivery of a patient report to the physician. As such, the Company takes assignment of benefits and the risk of collection with the third‑party payor. The Company usually bills the patient directly for amounts owed after multiple requests for payment have been denied or only partially paid by the insurance carrier. The Company pursues case‑by‑case reimbursement where policies are not in place or payment history has not been established.
	The Company’s product revenues for tests performed are recognized when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Criterion (1) is satisfied when the Company has an arrangement to pay or a contract with the payor in place addressing reimbursement for the Oncotype DX test. In the absence of such arrangements, the Company considers that criterion (1) is satisfied when a third‑party payor pays the Company for the test performed. Criterion (2) is satisfied when the Company performs the test and generates and delivers to the physician, or makes available on its web portal, a patient report. When evaluating whether the fee is fixed or determinable and collectibility, we consider whether we have sufficient history to reliably estimate the total fee that will be received from a payor and a payor’s individual payment patterns.  Determination of criteria (3) and (4) are based on management’s judgments regarding whether the fee charged for products or services delivered is fixed or determinable, and the collectability of those fees under any contract or arrangement. Based upon at least several months of payment history, the Company reviews the number of tests paid against the number of tests billed and the payor’s outstanding balance for unpaid tests to determine whether payments are being made at a consistently high percentage of tests billed and at appropriate amounts given the contracted payment amount. The estimated accrual amounts per test, recorded upon delivery of a patient report, are calculated for each accrual payor and are based on the contracted price adjusted for individual payment patterns resulting from co-payment amounts and excluded services in healthcare plans. When a payment received for an individual test is either higher or lower than the estimated accrual amount, we recognize the difference as either cash revenue, in the case of higher payments, or a write off to bad debt expense, in the case of lower payments.
	To the extent all criteria set forth above are not met when test results are delivered, product revenues are recognized when cash is received from the payor.
	The Company has exclusive distribution agreements for one or more of its Oncotype DX tests with distributors covering more than 90 countries. The distributor generally provides certain marketing and administrative services to the Company within its territory. As a condition of these agreements, the distributor generally pays the Company an agreed upon fee per test and the Company processes the tests. The same revenue recognition criteria described above generally apply to tests received through distributors. To the extent all criteria set forth above are not met when test results are delivered, product revenues are generally recognized when cash is received from the distributor.
	From time to time, the Company receives requests for refunds of payments, generally due to overpayments made by third party‑payors. Upon becoming aware of a refund request, the Company establishes an accrued liability for tests covered by the refund request until such time as the Company determines whether or not a refund is due. Accrued refunds were $944,000 and $770,000 at December 31, 2014 and 2013, respectively.
	Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case‑by‑case basis according to the facts and circumstances applicable to a given contract. Under certain contracts, the Company’s input, measured in terms of full‑time equivalent level of effort or running a set of assays through its clinical reference laboratory under a contractual protocol, triggers payment obligations, and revenues are recognized as costs are incurred or assays are processed. Certain contracts have payments that are triggered as milestones are completed, such as completion of a successful set of experiments. Milestones are assessed on an individual basis and revenue is recognized when these milestones are achieved, as evidenced by acknowledgment from collaborators, provided that (1) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement and (2) the milestone payment is non‑refundable. Where separate milestones do not meet these criteria, the Company typically defaults to a performance‑based model, such as revenue recognition following delivery of effort as compared to an estimate of total expected effort.
	Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met.
Cost of Product Revenues	Cost of Product Revenues
	Cost of product revenues includes the cost of materials, direct labor, equipment and infrastructure expenses associated with processing tissue samples (including sample accessioning, histopathology, anatomical pathology, paraffin extraction, reverse transcription polymerase chain reaction (“RT‑PCR”), quality control analyses and shipping charges to transport tissue samples) and license fees. Infrastructure expenses include allocated facility occupancy and information technology costs. Costs associated with performing the Company’s tests are recorded as tests are processed. Costs recorded for tissue sample processing and shipping charges represent the cost of all the tests processed during the period regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of product revenues and fixed annual payments relating to the launch and commercialization of the Company’s tests are recorded as license fees in cost of product revenues at the time product revenues are recognized or in accordance with other contractual obligations.
Research and Development Expenses	Research and Development Expenses
	Research and development expenses are comprised of costs incurred to develop technology and carry out clinical studies and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, and other outside costs. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical and pharmaceutical companies. Research and development costs are expensed as incurred.
	The Company enters into collaboration and clinical trial agreements with clinical collaborators and records these costs as research and development expenses. The Company records accruals for estimated study costs comprised of work performed by its collaborators under contract terms. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are delivered or the related services are performed.
Stock-based Compensation	Stock‑based Compensation
	The Company uses the Black‑Scholes option valuation model, single‑option approach, which requires the use of estimates such as stock price volatility and expected option lives, as well as expected option forfeiture rates, to value employee stock‑based compensation at the date of grant, and recognizes stock‑ based compensation expense ratably over the requisite service period.
	Equity instruments granted to non‑employees are also valued using the Black‑Scholes option valuation model and are subject to periodic revaluation over their vesting terms. The Company did not grant any stock options to non‑employee consultants during any of the years presented.
401(k) Plan	401(k) Plan
	Substantially all of the Company’s employees are eligible to participate in its defined contribution plan qualified under Section 401(k) of the Internal Revenue Code. The Company contributed dollar for dollar matching of employee contributions up to a maximum of $2,000,  $1,000, and $1,000 for the years ended December 31, 2014, 2013 and 2012, respectively, for each employee per year based on a full calendar year of service. The match is funded concurrently with a participant’s semi‑monthly contributions to the 401(k) Plan. The Company recorded expense for its contributions under the 401(k) Plan of $1.9 million,  $718,000 and $610,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
Foreign Currency Transactions	Foreign Currency Transactions
	Net foreign currency transaction gains or losses are included in other income (expense), net on the Company’s consolidated statement of operations. Net foreign currency transaction losses totaled $790,000,  $158,000 and $46,000 for the years ended December 31, 2014, 2013 and 2012, respectively.
Comprehensive Gain or Loss	Comprehensive Gain or Loss
	Other comprehensive gain or loss consists of unrealized gains and losses on available‑for‑sale securities.
Leases	Leases
	The Company enters into lease agreements for its laboratory and office facilities. These leases are classified as operating leases. Rent expense is recognized on a straight‑line basis over the term of the lease. Incentives granted under the Company’s facilities leases, including allowances to fund leasehold improvements and rent holidays, are capitalized and are recognized as reductions to rental expense on a straight‑line basis over the term of the lease.
Guarantees and Indemnifications	Guarantees and Indemnifications
	The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2014 and 2013.

Net_Income_Loss_Per_Share_Tabl

Net Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Net Income (Loss) Per Share
Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net income (loss) per share
		Year Ended December 31,
		2014		2013		2012
		(In thousands except
		per share data)
	Numerator:
	Net income (loss)	$	-24,592	$	-12,757	$	8,249
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net income (loss) per share		31,453		30,512		30,326
	Effect of dilutive securities:
	Options to purchase common stock		—		—		1,704
	Restricted stock units		—		—		122
	Total		—		—		1,826
	Weighted-average shares of common stock outstanding used in the calculation of diluted net income (loss) per share		31,453		30,512		32,152
	Basic net income (loss) per share	$	-0.78	$	-0.42	$	0.27
	Diluted net income (loss) per share	$	-0.78	$	-0.42	$	0.26

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements
Schedule of financial instruments measured at fair value on recurring basis		Actively Quoted		Significant
		Markets for		Other		Significant
		Identical		Observable		Unobservable		Balance at
		Assets		Inputs		Inputs		December 31,
		Level 1		Level 2		Level 3		2014
		(In thousands)
	As of December 31, 2014:
	Assets
	Money market deposits	$	12,397	$	—	$	—	$	12,397
	Commercial paper		—		29,749		—		29,749
	Corporate debt securities		—		46,435		—		46,435
	Total	$	12,397	$	76,184	$	—	$	88,581
		Actively Quoted		Significant
		Markets for		Other		Significant
		Identical		Observable		Unobservable		Balance at
		Assets		Inputs		Inputs		December 31,
		Level 1		Level 2		Level 3		2013
		(In thousands)
	As of December 31, 2013:
	Assets
	Money market deposits	$	15,690	$	—	$	—	$	15,690
	Commercial paper		—		37,643		—		37,643
	Corporate debt securities		—		35,428		—		35,428
	Total	$	15,690	$	73,071	$	—	$	88,761
Summary of available-for-sale marketable securities		December 31, 2014
		Amortized		Unrealized		Unrealized		Estimated
		Cost		Gains		Losses		Fair Value
		(In thousands)
	Commercial paper	$	29,730	$	19	$	—	$	29,749
	Corporate debt securities		44,219		—		-34		44,185
	Total	$	73,949	$	19	$	-34	$	73,934
		December 31, 2013
		Amortized		Unrealized		Unrealized		Estimated
		Cost		Gains		Losses		Fair Value
		(In thousands)
	Commercial paper	$	36,625	$	18	$	—	$	36,643
	Corporate debt securities		35,434		3		-9		35,428
	Total	$	72,059	$	21	$	-9	$	72,071
Schedule of the breakdown of available-for-sale marketable securities with unrealized losses
		In a Loss Position for
		Less Than 12 Months
		Gross
		Unrealized		Estimated
	As of December 31, 2014:	Losses		Fair Value
		(In thousands)
	Corporate debt securities	$	-34	$	42,282
	Total	$	-34	$	42,282

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property and Equipment
Summary of the Company's property and equipment
		December 31,
		2014		2013
		(In thousands)
	Laboratory equipment	$	24,685	$	23,402
	Computer equipment		9,198		8,856
	Computer software—internal use		5,075		4,182
	Furniture and fixtures		3,607		3,336
	Leasehold improvements		17,902		14,886
	Work in progress		7,307		7,149
			67,774		61,811
	Less accumulated depreciation and amortization		-45,914		-43,521
	Total	$	21,860	$	18,290

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Expenses and Other Current Liabilities
Summary of the Company's accrued expenses and other current liabilities
		December 31,
		2014		2013
		(In thousands)
	Accrued expenses	$	4,003	$	3,610
	Accrued professional and other service fees		1,273		1,401
	Accrued refunds		944		770
	Accrued collaboration expense		2,862		908
	Accrued taxes payable		194		278
	Other current liabilities		1,168		389
	Total	$	10,444	$	7,356

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments
Schedule of future non-cancelable commitments under operating leases
		Annual
		Payments
		(In thousands)
	Years Ending December 31,
	2015	$	3,928
	2016		3,872
	2017		3,867
	2018		2,476
	2019		504
	Total minimum payments	$	14,647

Capital_Stock_Tables

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Capital Stock
Schedule of shares of common stock reserved for future issuance
		Number of
		Shares
		(In thousands)
	Shares to be issued upon exercise of outstanding stock options and vesting of restricted stock units (RSUs)	4,420
	Shares available for future stock option and RSU grants, settlement of employee stock purchase plan (ESPP) and restricted stock to be issued to outside directors in lieu of director fees	1,746
	Shares of common stock reserved for future issuance	6,166

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Summary of option activity
							Weighted-Average
		Outstanding Options					Remaining		Aggregate
		Number of		Weighted-Average			Contractual		Intrinsic
		Shares		Exercise Price			Life		Value
		(In thousands)		(In years)					(In thousands)
	Balance at December 31, 2013	4,109		$	20.57
	Options granted	442		$	30.35
	Options exercised	-553		$	14.11
	Options forfeited	-221		$	30.18
	Balance at December 31, 2014	3,777		$	22.10		5.1		$	37,768
	Exercisable at December 31, 2014	3,119		$	20.45		4.3		$	36,327
	Vested and expected to vest at December 31, 2014	3,729		$	21.99		5.0		$	37,681
Summary of RSU activity
				Weighted-Average
		Number of		Grant Date Fair
		Shares		Value
		(In thousands)
	Balance at December 31, 2013	681		$	29.46
	RSUs granted	383		$	29.05
	RSUs vested	-327		$	28.25
	RSUs cancelled	-107		$	30.54
	Balance at December 31, 2014	630		$	29.65
Schedule of the impact of employee stock-based compensation expense on selected statement of operations line items
		Year Ended December 31,
		2014			2013			2012
		(In thousands)
	Cost of product revenues	$	497		$	483		$	441
	Research and development		4,569			4,873			3,992
	Selling and marketing		4,396			4,369			4,191
	General and administrative		7,076			7,732			6,480
	Total	$	16,538		$	17,457		$	15,104
Schedule of weighted-average fair values and assumptions used in calculation of fair value of stock options and employee stock purchase plan
		Year Ended December 31,
		2014			2013			2012
	Expected volatility:
	Stock options		44	%		46	%		46	%
	ESPP		37	%		39	%		43	%
	Risk-free interest rate:
	Stock options		1.97	%		1.40	%		1.23	%
	ESPP		0.08	%		0.11	%		0.09	%
	Expected life in years:
	Stock options		6.61			6.64			6.98
	ESPP		0.50			0.50			0.50
	Weighted-average fair value:
	Stock options	$	14.13		$	14.11		$	14.51
	ESPP	$	7.24		$	7.82			7.67
Performance-Based Vesting
Summary of RSU activity
				Weighted-Average
		Number of		Grant Date Fair
		Shares		Value
		(In thousands)
	Balance at December 31, 2013	—		$	—
	PVRSUs granted	14		$	27.21
	PVRSUs vested	—		$	—
	PVRSUs cancelled	—		$	—
	Balance at December 31, 2014	14		$	27.21

Segment_Information_Tables

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Information
Summary of total revenues from customers, payors and collaboration partners by geographic region
		Year Ended December 31,
		2014		2013		2012
		(In thousands)
	United States	$	230,657	$	223,662	$	207,508
	Outside of the United States		45,049		37,933		27,665
	Total revenues	$	275,706	$	261,595	$	235,173

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes
Schedule of components of the Company's income (loss) before income taxes
		Year Ended December 31,
		2014		2013		2012
		(In thousands)
	Domestic	$	-25,337	$	-13,294	$	8,018
	Foreign		1,138		883		653
	Total income (loss) before income taxes	$	-24,199	$	-12,411	$	8,671
Schedule of components of the Company's income tax expense (benefit)
		Year Ended
		December 31,
		2014		2013		2012
		(In thousands)
	Current expense (benefit):
	Federal	$	—	$	-22	$	111
	State		40		57		99
	Foreign		353		311		212
	Total income tax expense	$	393	$	346	$	422
Schedule of reconciliation of income tax expense (benefit) and the amount computed by applying the statutory federal income tax rate
		Year Ended December 31,
		2014		2013		2012
		(In thousands)
	Federal tax at statutory rate	$	-8,470	$	-4,344	$	3,035
	Non-deductible officer compensation		79		—		—
	Stock-based compensation		789		1,149		1,659
	Non-deductible meals and entertainment		531		507		492
	Net operating losses not used (used)		7,478		2,999		-4,973
	Federal alternative minimum tax		—		—		120
	State tax, net of federal benefit		26		37		64
	Other		-40		-2		25
	Total income tax expense	$	393	$	346	$	422
Schedule of significant components of deferred tax assets and liabilities
		December 31,
		2014		2013
		(In thousands)
	Deferred tax assets:
	Net operating loss carryforwards	$	35,060	$	30,970
	Stock-based compensation		10,210		9,150
	Research tax credits		12,500		9,580
	Fixed assets		3,520		3,200
	Capitalized costs		3,590		3,860
	Other		6,890		5,080
	Total deferred tax assets		71,770		61,840
	Valuation allowance		-71,770		-61,840
	Net deferred tax assets	$	—	$	—
Summary of the activity related to unrecognized tax benefits
		Year Ended
		December 31,
		2014		2013		2012
		(In thousands)
	Balance at January 1	$	2,160	$	875	$	839
	Increase (decrease) related to prior year tax positions		-907		74		-3
	Increase related to current year tax positions		347		1,211		39
	Balance at December 31	$	1,600	$	2,160	$	875

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Selected Quarterly Financial Data (Unaudited)
Schedule of selected quarterly unaudited consolidated statement of operations information
	Quarter Ended	March 31,		June 30,		September 30,		December 31,
		(In thousands, except per share data)
	2014:00:00
	Total revenues	$	67,002	$	70,477	$	69,101	$	69,126
	Product revenues		67,002		70,477		69,101		69,126
	Cost of product revenues		12,055		12,207		11,979		12,501
	Net loss		-7,445		-4,618		-6,262		-6,267
	Basic and diluted net loss per common share	$	-0.24	$	-0.15	$	-0.2	$	-0.2
	2013:00:00
	Total revenues	$	63,094	$	63,691	$	65,990	$	68,819
	Product revenues		62,709		63,691		65,732		67,060
	Cost of product revenues		9,746		10,757		10,781		10,815
	Net income (loss)		-883		-2,994		488		-9,369
	Basic net income (loss) per common share	$	-0.03	$	-0.1	$	0.02	$	-0.3
	Diluted net income (loss) per common share	$	-0.03	$	-0.1	$	0.02	$	-0.3

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies Principles of Consolidation (Details)	12 Months Ended
	Dec. 31, 2014
	subsidiary
Principles of Consolidation
Number of wholly-owned subsidiaries	2
Genomic Health International Holdings, LLC
Principles of Consolidation
Number of wholly-owned subsidiaries	10

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies Concentration of Risk (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Concentration of Risk
Number of products from which the majority of the entity's product revenues have been derived	1
Product revenues | Third-party payor
Concentration of Risk
Number of products from which the majority of the entity's product revenues have been derived	1
Product revenues | Third-party payor | Medicare
Concentration of Risk
Concentration risk percentage	20.00%	21.00%	22.00%
Net accounts receivable | Third-party payor | Medicare
Concentration of Risk
Concentration risk percentage	27.00%	28.00%

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2012	Oct. 31, 2012	Aug. 31, 2012	Mar. 31, 2011	Dec. 31, 2010
	Test
	country
Allowance for Doubtful Accounts
Allowance for doubtful accounts	$3,628,000	$1,907,000
Write-offs for doubtful accounts recorded against allowance	5,400,000
Bad debt expense	6,700,000	6,200,000	3,400,000
Investments in Privately Held Companies
Impairment recognized		643,000
Carrying value of investments in privately held companies	13,900,000	11,900,000
Impairment of Long-lived Assets
Write-off of previously capitalized software costs		663,000
Impairment loss for equipment classified as held for sale	265,000
Impairment losses equipment disposed prior to placing it in service	110,000
Revenue Recognition
Minimum number of Oncotype DX tests by exclusive distribution agreements	1
Minimum number of countries covered for distribution agreements establishment	90
Accrued refunds	944,000	770,000
401(k) Plan
Maximum amount of matching employer contribution for each employee per year	2,000	1,000	1,000
Contributions expensed	1,900,000	718,000	610,000
Foreign Currency Transactions
Net foreign currency transaction losses	790,000	158,000	46,000
Private company 1, Cost Method Investment
Investments in Privately Held Companies
Additional investment made in preferred stock of a private company				400,000
Percentage of ownership interest in private company accounted for under the cost method of accounting				16.00%
Impairment recognized		643,000
Carrying value of investments in privately held companies		0
Private company 2
Investments in Privately Held Companies
Additional investment made in preferred stock of a private company					10,600,000	1,000,000
Percentage of ownership interest in private company accounted for under the cost method of accounting	8.00%	12.00%				19.00%
Investment in redeemable preferred stock							2,300,000
Investment in the redeemable preferred stock of a private company, percent of the entity's outstanding voting shares							21.00%
Impairment recognized	0
Carrying value of investments in privately held companies	13,900,000	11,900,000
Private company 1, Cost Method Investment
Investments in Privately Held Companies
Amount invested in preferred stock of a private company								$500,000
Percentage of ownership interest in private company								21.00%
Property and equipment | Minimum
Property and Equipment and Internal-Use Software
Estimated useful lives of the assets	3 years
Property and equipment | Maximum
Property and Equipment and Internal-Use Software
Estimated useful lives of the assets	7 years

Net_Income_Loss_Per_Share_Deta

Net Income (Loss) Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net income (loss)	($6,267)	($6,262)	($4,618)	($7,445)	($9,369)	$488	($2,994)	($883)	($24,592)	($12,757)	$8,249
Denominator:
Weighted-average shares of common stock outstanding used in the calculation of basic net income (loss) per share									31,453,000	30,512,000	30,326,000
Effect of dilutive securities:
Effect of dilutive securities (in shares)											1,826,000
Weighted-average shares of common stock outstanding used in the calculation of diluted net income (loss) per share									31,453,000	30,512,000	32,152,000
Basic net income (loss) per common share (in dollars per share)					($0.30)	$0.02	($0.10)	($0.03)	($0.78)	($0.42)	$0.27
Diluted net income (loss) per share (in dollars per share)					($0.30)	$0.02	($0.10)	($0.03)	($0.78)	($0.42)	$0.26
Options to purchase common stock
Effect of dilutive securities:
Effect of dilutive securities (in shares)											1,704,000
Awards outstanding but not included in the computation of diluted net income (loss) per share (in shares)									1,100,000	1,500,000	119,000
Restricted Stock Units
Effect of dilutive securities:
Effect of dilutive securities (in shares)											122,000
Awards outstanding but not included in the computation of diluted net income (loss) per share (in shares)									150,000	156,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets measured at fair value on a recurring basis:
Transfer of assets from level 1 to level 2	$0	$0
Transfer of assets from level 2 to level 1	0	0
Transfer of liabilities from level 1 to level 2	0	0
Transfer of liabilities from level 2 to level 1	0	0
Recurring basis | Actively Quoted Markets for Identical Assets Level 1
Assets measured at fair value on a recurring basis:
Total assets at fair value	12,397	15,690
Recurring basis | Actively Quoted Markets for Identical Assets Level 1 | Money market deposits
Assets measured at fair value on a recurring basis:
Total assets at fair value	12,397	15,690
Recurring basis | Significant Other Observable Inputs Level 2
Assets measured at fair value on a recurring basis:
Total assets at fair value	76,184	73,071
Recurring basis | Significant Other Observable Inputs Level 2 | Commercial paper
Assets measured at fair value on a recurring basis:
Total assets at fair value	29,749	37,643
Recurring basis | Significant Other Observable Inputs Level 2 | Corporate debt securities
Assets measured at fair value on a recurring basis:
Total assets at fair value	46,435	35,428
Recurring basis | Fair value
Assets measured at fair value on a recurring basis:
Total assets at fair value	88,581	88,761
Recurring basis | Fair value | Money market deposits
Assets measured at fair value on a recurring basis:
Total assets at fair value	12,397	15,690
Recurring basis | Fair value | Commercial paper
Assets measured at fair value on a recurring basis:
Total assets at fair value	29,749	37,643
Recurring basis | Fair value | Corporate debt securities
Assets measured at fair value on a recurring basis:
Total assets at fair value	$46,435	$35,428

Fair_Value_Measurements_Availa

Fair Value Measurements Available-For-Sale Marketable Securities (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Marketable securities classified as available-for-sale
Amortized Cost	$73,949	$72,059
Unrealized Gains	19	21
Unrealized Losses	-34	-9
Estimated Fair Value	73,934	72,071
Realized gains on available-for-sale marketable securities	0	0	0
Realized losses on available-for-sale marketable securities	0	0	0
Commercial paper
Marketable securities classified as available-for-sale
Amortized Cost	29,730	36,625
Unrealized Gains	19	18
Estimated Fair Value	29,749	36,643
Corporate debt securities
Marketable securities classified as available-for-sale
Amortized Cost	44,219	35,434
Unrealized Gains		3
Unrealized Losses	-34	-9
Estimated Fair Value	$44,185	$35,428

Fair_Value_Measurements_Availa1

Fair Value Measurements Available-For-Sale Marketable Securities with Unrealized Losses (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements
In a Loss Position for Less Than 12 Months, Gross Unrealized Losses	($34)
In a Loss Position for Less Than 12 Months, Estimated Fair Value	42,282
Maximum contractual maturities of Company's available-for-sale marketable securities	1 year	1 year
Corporate debt securities
Fair Value Measurements
In a Loss Position for Less Than 12 Months, Gross Unrealized Losses	-34
In a Loss Position for Less Than 12 Months, Estimated Fair Value	$42,282

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property and Equipment
Property and equipment, gross	$67,774,000	$61,811,000
Less accumulated depreciation and amortization	-45,914,000	-43,521,000
Depreciation and amortization expense	6,700,000	6,100,000	5,300,000
Total	21,860,000	18,290,000
Laboratory equipment
Property and Equipment
Property and equipment, gross	24,685,000	23,402,000
Computer equipment
Property and Equipment
Property and equipment, gross	9,198,000	8,856,000
Computer software-internal use
Property and Equipment
Property and equipment, gross	5,075,000	4,182,000
Furniture and fixtures
Property and Equipment
Property and equipment, gross	3,607,000	3,336,000
Leasehold improvements
Property and Equipment
Property and equipment, gross	17,902,000	14,886,000
Work in progress
Property and Equipment
Property and equipment, gross	$7,307,000	$7,149,000

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities
Accrued expenses	$4,003	$3,610
Accrued professional and other service fees	1,273	1,401
Accrued refunds	944	770
Accrued collaboration expense	2,862	908
Accrued taxes payable	194	278
Other current liabilities	1,168	389
Total	$10,444	$7,356

Collaboration_and_Commercial_T1

Collaboration and Commercial Technology Licensing Agreements (Details) (USD $)	3 Months Ended	12 Months Ended			3 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Collaboration and Commercial Technology Licensing Agreements
Up-front payment	$9,000,000
Specimen transfer agreements
Collaboration and Commercial Technology Licensing Agreements
Collaboration expense		6,400,000	12,600,000	1,900,000
Oncotype DX DCIS score agreement
Fixed annual payments
2015	604,000	604,000
2016	604,000	604,000
2017	504,000	504,000
Exclusive license agreement
Collaboration and Commercial Technology Licensing Agreements
Up-front payment					9,000,000
Collaboration payments and costs
Agreement break-up fee maximum			3,000,000		3,000,000
Technology license agreements
Collaboration and Commercial Technology Licensing Agreements
Costs recorded under collaborative arrangements		9,500,000	8,900,000	8,000,000
Oncotype DX colon cancer test and Oncotype DX prostate cancer test
Fixed future annual payments, exclusive of royalty payments
2015	550,000	550,000
Genomic Prostate Score agreement
Collaboration payments and costs
Estimated total remaining obligation, including milestone payments		$5,200,000

Collaboration_and_Commercial_T2

Collaboration and Commercial Technology Licensing Agreements Contract Research Arrangements (Details) (Collaborative Diagnostic Development Agreement with Pfizer Inc., USD $)	1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Nov. 30, 2007
Collaborative Diagnostic Development Agreement with Pfizer Inc.
Contract research arrangements
Initial payment received upon joint agreement		$1.50
Payment receivable upon joint agreement on gene identification plan		2.2
Additional payments receivable to conduct next phase of development		5
Final payment receivable upon completion of clinical validation		1.5
Amount recognized upon completion of milestone	$1.50

Commitments_Details

Commitments (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2010	Oct. 31, 2009	Aug. 31, 2013	Sep. 30, 2005	Jan. 31, 2007	Jul. 31, 2014	31-May-14	31-May-10
					sqft	sqft	sqft	sqft	sqft	sqft	sqft
Non-cancelable operating leases
Rent expense	$3,700,000	$3,000,000	$3,700,000
Non-cancelable commitments under operating leases
2015	3,928,000
2016	3,872,000
2017	3,867,000
2018	2,476,000
2019	504,000
Total minimum payments	14,647,000
Leased laboratory and office space located in Redwood City, California
Non-cancelable operating leases
Area leased under non-cancelable operating lease agreement (in square feet)							48,000
Period of time for which entity has an option to extend lease term				5 years
Lease incentive obligations							834,000
Leased laboratory and office space located near the leased facility in Redwood City, California
Non-cancelable operating leases
Area leased under non-cancelable operating lease agreement (in square feet)								48,000
Period of time for which entity has an option to extend lease term				5 years
Lease incentive obligations								283,000
Leased office space located near the leased facility in Redwood City, California
Non-cancelable operating leases
Area leased under non-cancelable operating lease agreement (in square feet)					30,500
Period of time for which entity has an option to extend lease term					5 years
Lease incentive obligations					307,000
Second leased laboratory and office space located near the leased facility in Redwood City, California
Non-cancelable operating leases
Area leased under non-cancelable operating lease agreement (in square feet)						18,400
Period of time for which entity has an option to extend lease term						5 years
Additional area leased (in square feet)									5,500
Lease incentive obligations									$358,000
Leased office space located in Geneva, Switzerland | European subsidiary
Non-cancelable operating leases
Area leased under non-cancelable operating lease agreement (in square feet)											2,500
Additional area leased (in square feet)										5,000

Capital_Stock_Details

Capital Stock (Details) (USD $)	1 Months Ended		12 Months Ended
	Feb. 28, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
	Transaction
Capital Stock
Common stock outstanding (in shares)			30,964,086		31,911,901
Capital Stock
Shares of common stock reserved for future issuance					6,166,000
Treasury Stock
Amount of common stock to be repurchased on an accelerated basis under accelerated share repurchase agreement		$30,000,000		$30,000,000
Amount paid to the financial institution to settle the initial purchase transaction		$30,000,000	$15,000	$30,095,000
Number of common shares received under accelerated share repurchase agreement	77,257	984,074
Average purchase price of common stock from the accelerated share repurchase program (in dollars per share)	$28.27
Number of separate transactions	2
Exercise of outstanding stock options and vesting of restricted stock units (RSUs)
Capital Stock
Shares of common stock reserved for future issuance					4,420,000
Stock option and restricted stock unit grants, settlement of employee stock purchase plan (ESPP) and restricted stock to be issued to outside directors in lieu of director fees
Capital Stock
Shares of common stock reserved for future issuance					1,746,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	0 Months Ended	12 Months Ended
	Jun. 08, 2009	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 08, 2005
2005 Stock Incentive Plan
Stock-based compensation
Shares of common stock reserved for issuance under the ESPP						5,000,000
Increase in shares reserved for issuance	3,980,000
Shares of common stock available for future grant		985,722
Employee Stock Purchase Plan
Stock-based compensation
Shares of common stock reserved for issuance under the ESPP		1,250,000
Shares of common stock available for future grant		759,738
Maximum period for offerings under ESPP		27 months
Length of purchase period under ESPP		6 months
Number of shares issued		191,318	152,881	146,063
Unrecognized compensation expense (in dollars)		$592,000
Weighted-average period of recognition of unrecognized stock-based compensation expense		5 months
Minimum | Employee Stock Purchase Plan
Stock-based compensation
Exercise price as a percentage of the fair market value of the company's stock		85.00%
Stock Options | Vice president and above ranking other than executive officers
Stock-based compensation
Target percentage of equity grant value					50.00%
Stock Options | Executive officers
Stock-based compensation
Target percentage of equity grant value					75.00%
Incentive Stock Sptions | Minimum
Stock-based compensation
Exercise price as a percentage of the fair market value of the company's stock		100.00%
Incentive Stock Sptions | Maximum
Stock-based compensation
Term of incentive stock options from the date of grant		10 years
Nonstatutory Stock Options | Minimum
Stock-based compensation
Exercise price as a percentage of the fair market value of the company's stock		80.00%
Nonstatutory Stock Options | Outside directors
Stock-based compensation
Exercise price as a percentage of the fair market value of the company's stock		100.00%
Nonstatutory Stock Options | Outside directors | End of first year
Stock-based compensation
Vesting percentage		25.00%
Vesting period, after the first anniversary, in which the options vest monthly		3 years
Nonstatutory Stock Options | Outside directors | Maximum
Stock-based compensation
Term of incentive stock options from the date of grant		10 years
Term of stock options after termination of the outside directors' service		12 months
Nonstatutory Stock Options | Outside directors not initially elected at annual meeting
Stock-based compensation
Vesting period		1 year
Restricted Stock Units
Stock-based compensation
Stock outstanding (in shares)		630,000	681,000
Weighted-average period of recognition of unrecognized stock-based compensation expense		1 year 9 months 18 days
Number of equal annual installments		3
Restricted Stock Units | Performance-Based Vesting
Stock-based compensation
Stock outstanding (in shares)		13,533
Stock awards other than options
Grant-date fair value (in dollars)		$368,000
Number of performance milestones on which vesting of awards is based		3
Restricted Stock Units | Minimum | Vesting on achievement of revenue milestone
Stock-based compensation
Vesting percentage		0.00%
Restricted Stock Units | Minimum | Vesting on achievement of tests delivered milestone
Stock-based compensation
Vesting percentage		0.00%
Restricted Stock Units | Minimum | Vesting on achievement of reimbursement-related milestone
Stock-based compensation
Vesting percentage		0.00%
Restricted Stock Units | Maximum | Performance-Based Vesting
Stock-based compensation
Vesting percentage		100.00%
Restricted Stock Units | Maximum | Vesting on achievement of revenue milestone
Stock-based compensation
Vesting percentage		100.00%
Restricted Stock Units | Maximum | Vesting on achievement of tests delivered milestone
Stock-based compensation
Vesting percentage		100.00%
Restricted Stock Units | Maximum | Vesting on achievement of reimbursement-related milestone
Stock-based compensation
Vesting percentage		33.33%
Restricted Stock Units | Vice president and above ranking other than executive officers
Stock-based compensation
Target percentage of equity grant value					50.00%
Restricted Stock Units | Executive officers
Stock-based compensation
Target percentage of equity grant value					25.00%

StockBased_Compensation_Stock_

Stock-Based Compensation Stock Option Activity (Details) (Stock Options, USD $)	12 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options
Number of Shares
Options outstanding at the beginning of the period (in shares)	4,109
Options granted (in shares)	442
Options exercised (in shares)	553
Options forfeited (in shares)	-221
Options outstanding at the end of the period (in shares)	3,777	4,109
Exercisable at the end of the period (in shares)	3,119
Vested and expected to vest at the end of the period (in shares)	3,729
Weighted-Average Exercise Price
Options outstanding at the beginning of the period (in dollars per share)	$20.57
Options granted (in dollars per share)	$30.35
Options exercised (in dollars per share)	$14.11
Options forfeited (in dollars per share)	$30.18
Options outstanding at the end of the period (in dollars per share)	$22.10	$20.57
Exercisable at the end of the period (in dollars per share)	$20.45
Vested and expected to vest at the end of the period (in dollars per share)	$21.99
Weighted-Average Remaining Contractual Life
Options outstanding at the end of the period	5 years 1 month 6 days
Exercisable at the end of the period	4 years 3 months 18 days
Vested and expected to vest at the end of the period	5 years
Aggregate Intrinsic Value
Options outstanding at the end of the period (in dollars)	$37,768,000
Exercisable at the end of the period (in dollars)	36,327,000
Vested and expected to vest at the end of the period (in dollars)	37,681,000
Additional disclosure related to options
Intrinsic value (in dollars)	8,200,000	13,500,000	15,300,000
Fair value of shares vested (in dollars)	$6,000,000	$7,300,000	$7,900,000

StockBased_Compensation_RSU_Ac

Stock-Based Compensation RSU Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Units
Number of Shares
Balance at the beginning of the period (in shares)	681,000
Granted (in shares)	383,000
Vested (in shares)	-327,000
Cancelled (in shares)	-107,000
Balance at the end of the period (in shares)	630,000	681,000
Weighted-Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per share)	$29.46
Granted (in dollars per share)	$29.05	$30.56	$29.81
Vested (in dollars per share)	$28.25
Cancelled (in dollars per share)	$30.54
Balance at the end of the period (in dollars per share)	$29.65	$29.46
Additional Disclosure
Fair value (in dollars)	$9,100,000	$6,900,000
Restricted Stock Units | Performance-Based Vesting
Number of Shares
Granted (in shares)	14,000	0
Vested (in shares)	0
Balance at the end of the period (in shares)	14,000
Weighted-Average Grant Date Fair Value
Granted (in dollars per share)	$27.21
Balance at the end of the period (in dollars per share)	$27.21
Restricted Stock | Outside directors
Number of Shares
Granted (in shares)	8,209	7,769	5,512
Weighted-Average Grant Date Fair Value
Granted (in dollars per share)	$27.97	$29.54	$30.79
Additional Disclosure
Fair value (in dollars)	$230,000	$230,000	$172,000

StockBased_Compensation_Employ

Stock-Based Compensation Employee Stock-Based Compensation Expense (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Based Compensation Expense
Stock-based compensation expense (in dollars)	$16,538,000	$17,457,000	$15,104,000
Unvested Stock Options
Employee Stock Based Compensation Expense
Unrecognized compensation expense (in dollars)	6,400,000
Weighted-average period of recognition of unrecognized stock-based compensation expense	2 years 4 months 24 days
Restricted Stock Units
Employee Stock Based Compensation Expense
Unrecognized compensation expense (in dollars)	10,700,000
Weighted-average period of recognition of unrecognized stock-based compensation expense	1 year 9 months 18 days
Restricted Stock Units | Performance-Based Vesting
Employee Stock Based Compensation Expense
Unrecognized compensation expense (in dollars)	146,000
Weighted-average period of recognition of unrecognized stock-based compensation expense	10 months 24 days
Cost of product revenues | Employees
Employee Stock Based Compensation Expense
Stock-based compensation expense (in dollars)	497,000	483,000	441,000
Research and development | Employees
Employee Stock Based Compensation Expense
Stock-based compensation expense (in dollars)	4,569,000	4,873,000	3,992,000
Selling and marketing | Employees
Employee Stock Based Compensation Expense
Stock-based compensation expense (in dollars)	4,396,000	4,369,000	4,191,000
General and administrative | Employees
Employee Stock Based Compensation Expense
Stock-based compensation expense (in dollars)	$7,076,000	$7,732,000	$6,480,000

StockBased_Compensation_Valuat

Stock-Based Compensation Valuation Assumptions (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted-average fair values and assumptions used in calculation of fair value
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Employee Stock Purchase Plan
Weighted-average fair values and assumptions used in calculation of fair value
Expected volatility (as a percent)	37.00%	39.00%	43.00%
Risk-free interest rate (as a percent)	0.08%	0.11%	0.09%
Expected life	6 months	6 months	6 months
Weighted-average fair value (in dollars per share)	7.24	7.82	7.67
Stock Options
Weighted-average fair values and assumptions used in calculation of fair value
Expected volatility (as a percent)	44.00%	46.00%	46.00%
Risk-free interest rate (as a percent)	1.97%	1.40%	1.23%
Expected life	6 years 7 months 10 days	6 years 7 months 21 days	6 years 11 months 23 days
Weighted-average fair value (in dollars per share)	14.13	14.11	14.51

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	product								segment
									product
Segment Information
Number of business segments in which the entity operates									1
Number of products from which the majority of the entity's product revenues have been derived	1								1
Segment information
Total revenues	$69,126	$69,101	$70,477	$67,002	$68,819	$65,990	$63,691	$63,094	$275,706	$261,595	$235,173
United States
Segment information
Total revenues									230,657	223,662	207,508
Outside of the United States
Segment information
Total revenues									$45,049	$37,933	$27,665

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Components of income (loss) before income taxes
Domestic	($25,337)	($13,294)	$8,018
Foreign	1,138	883	653
Income (loss) before income taxes	-24,199	-12,411	8,671
Current expense (benefit):
Federal		-22	111
State	40	57	99
Foreign	353	311	212
Total income tax expense	393	346	422
Reconciliation of income tax expense (benefit) and the amount computed by applying the statutory federal income tax rate
Federal tax at statutory rate	-8,470	-4,344	3,035
Non-deductible officer compensation	79
Stock-based compensation	789	1,149	1,659
Non-deductible meals and entertainment	531	507	492
Net operating losses not used (used)	7,478	2,999	-4,973
Federal alternative minimum tax			120
State tax, net of federal benefit	26	37	64
Other	-40	-2	25
Total income tax expense	393	346	422
Deferred tax assets:
Net operating loss carryforwards	35,060	30,970
Stock-based compensation	10,210	9,150
Research tax credits	12,500	9,580
Fixed assets	3,520	3,200
Capitalized costs	3,590	3,860
Other	6,890	5,080
Total deferred tax assets	71,770	61,840
Valuation allowance	($71,770)	($61,840)

Income_Taxes_Net_Operating_Los

Income Taxes Net Operating Loss Carryforwards (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net operating loss carryforwards
Increase (decrease) in net valuation allowance	($9.90)	$7.20	$3.80
Net operating losses related to stock option benefits	27.9
Federal
Net operating loss carryforwards
Net operating loss carryforwards	115
Federal | Research and development.
Net operating loss carryforwards
Research and development tax credit carryforwards	9.3
State
Net operating loss carryforwards
Net operating loss carryforwards	86
State | Research and development.
Net operating loss carryforwards
Research and development tax credit carryforwards	$6.70

Income_Taxes_Activity_Related_

Income Taxes Activity Related to Unrecognized Tax Benefits (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Activity related to unrecognized tax benefits
Balance at the beginning of the period	$2,160,000	$875,000	$839,000
Increase related to prior year tax positions	-907,000
(Decrease) related to prior year tax positions		-74,000	-3,000
Increase related to current year tax positions	347,000	1,211,000	39,000
Balance at the end of the period	1,600,000	2,160,000	875,000
Unrecognized tax benefits
Interest and penalties	$6,400	$5,700	$6,800

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Selected Quarterly Financial Data (Unaudited)
Total revenues	$69,126,000	$69,101,000	$70,477,000	$67,002,000	$68,819,000	$65,990,000	$63,691,000	$63,094,000	$275,706,000	$261,595,000	$235,173,000
Product revenues	69,126,000	69,101,000	70,477,000	67,002,000	67,060,000	65,732,000	63,691,000	62,709,000	275,706,000	259,192,000	233,457,000
Cost of product revenues	12,501,000	11,979,000	12,207,000	12,055,000	10,815,000	10,781,000	10,757,000	9,746,000	48,742,000	42,100,000	37,018,000
Net income (loss)	-6,267,000	-6,262,000	-4,618,000	-7,445,000	-9,369,000	488,000	-2,994,000	-883,000	-24,592,000	-12,757,000	8,249,000
Basic and diluted net loss per common share (in dollars per share)	($0.20)	($0.20)	($0.15)	($0.24)
Basic net income (loss) per common share (in dollars per share)					($0.30)	$0.02	($0.10)	($0.03)	($0.78)	($0.42)	$0.27
Diluted net income ( loss) per common share (in dollars per share)					($0.30)	$0.02	($0.10)	($0.03)	($0.78)	($0.42)	$0.26
Up-front payment under a license agreement	$9,000,000

SCHEDULE_II_VALUATION_AND_QUAL1

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) (Allowance for Doubtful Accounts:, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts:
Movement in valuation and qualifying accounts
Balance at Beginning of Period	$1,907	$1,133	$1,206
Expenses	7,104	6,169	3,408
Deductions	5,383	5,395	3,481
Balance at End of Period	$3,628	$1,907	$1,133